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ABSTRACT OF DISSERTATION
Differential Abundance and Clustering Analysis with Empirical Bayes Shrinkage
Estimation of Variance (DASEV) for Proteomics and Metabolomics Data
Mass spectrometry (MS) is widely used for proteomic and metabolomic profiling of
biological samples. Data obtained by MS are often zero-inflated. Those zero values are
called point mass values (PMVs). Zero values can be further grouped into biological
PMVs and technical PMVs. The former type is caused by the absence of components
and the latter type is caused by detection limit. There is no simple solution to separate
those two types of PMVs. Mixture models were developed to separate the two types
of zeros apart and to perform the differential abundance analysis. However, we notice
that the mixture model can be unstable when the number of non-zero values is small.
In this dissertation, we propose a new differential abundance (DA) analysis method,
DASEV, which applies an empirical Bayes shrinkage estimation on variance. We hy-
pothesized that performance on variance estimation could be more robust and thus
enhance the accuracy of differential abundance analysis. Disregarding the issue the
mixture models have, the method has shown promising strategies to separate two
types of PMVs. We adapted the mixture distribution proposed in the original mix-
ture model design and assumed that the variances for all components follow a certain
distribution. We proposed to calculate the estimated variances by borrowing infor-
mation from other components via applying the assumed distribution of variance,
and then re-estimate other parameters using the estimated variances. We obtained
better and more stable estimations on variance, means abundances, and proportions
of biological PMVs, especially where the proportion of zeros is large. Therefore, the
proposed method achieved obvious improvements in DA analysis.
We also propose to extend the method for clustering analysis. To our knowledge,
commonly used cluster methods for MS omics data are only K-means and Hierarchi-
cal. Both methods have their own limitations while being applied to the zero-inflated
data. Model-based clustering methods are widely used by researchers for various data
types including zero-inflated data. We propose to use the extension (DASEV.C) as a
model-based cluster method. We compared the clustering performance of DASEV.C
with K-means and Hierarchical. Under certain scenarios, the proposed method re-
turned more accurate clusters than the standard methods.
We also develop an R package dasev for the proposed methods presented in this
dissertation. The major functions DASEV.DA and DASEV.C in this R package aim
to implement the Bayes shrinkage estimation on variance then conduct the differential
abundance and cluster analysis. We designed the functions to allow the flexibility for
researchers to specify certain input options.
KEYWORDS: Mass spectrometry, Zero inflated, Point mass values, Proteomics,
Metabolomics, Bayes shrinkage estimation
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Chapter 1 Introduction
In a 2007 review article published in Mass Spectrometry Reviews, the authors wrote:
Although the understanding of living organisms at the molecular system level is
still in its infancy, it is evident that comprehensive investigations of the “omics
cascade” with genomics, transcriptomics, proteomics, and metabolomics are im-
portant building blocks and will play a central role in this new science [1].
With the emerging advanced analytical techniques, the new “omics” era has ar-
rived. We have seen an enormous increase in the use of words with the “omics”
suffix in biological and biomedical sciences since late 1990s [2]. We applied the same
search phrase: “(genomics [MeSH] OR proteomics [MeSH] OR metabolomics [MeSH]
OR transcriptomics [MeSH]) AND humans [MeSH]”) used by Raja et al. (2017)
to obtain the counts of publications by 5-year intervals from PubMed (Figure 1.1).
The increasing trend shown in the figure is likely to continue with improvements in
advanced analytical techniques.
Figure 1.1: PubMed publications containing the search phrase “genomics [MeSH]
OR proteomics [MeSH] OR metabolomics [MeSH] OR transcriptomics [MeSH]) AND
humans [MeSH]” by 5-year intervals.
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1.1 The “Omics”
The word “Omics” refers to a study field in biology with the collective technologies
ending in “-omics” [3, 4]. The scale and complexity of biological data have been
exploding with the high-throughput (HTP) technologies being routinely used [5].
Comprehensive study of the omics cascade from genomics to metabolomics is key for
systematically understanding the functions of biological components and the effects
resulting from dynamic biological systems (Figure 1.2) [1].
Figure 1.2: The omics cascade.
With the continuing revolutions in Omics, biological and biomedical research are
now much more dynamic and complex. Thoroughly studying each omics field, and
systematically combining them together, could lead to a more comprehensive under-
standing of molecular biology [6].
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1.2 Mass Spectrometry
One widely used and powerful analytical instrument for getting HTP biological data
is Mass Spectrometry (MS). Data on the molecular weight of the components in
biological samples are measured by MS using mass-to-charge ratios [7]. This ana-
lytical tool plays an essential role in the comprehensive understanding of the omics
cascade [8]. Together with its various techniques, omics data produced by MS are
commonly used in biological and biomedical research.
Many reviews presenting the essential role of MS in the omics field are available
[1, 3, 4, 6–13]. MS used to be more expensive, take more time per sample, and have
lower sensitivity. Therefore, it was not cost and time efficient to put biological samples
with a high number of components through MS. However, with the rapid expansion in
related technologies, issues such as speed, sensitivity, throughput, and cost efficiency
have been improved significantly.
MS is now routinely used for various purposes including diagnostics, pathology,
and new treatment development [8, 11]. Some advantages of MS include increased
sensitivity, high mass resolution and accuracy, rapid speed, better separation, the
ability to process numerous components at once, and the capability to detect com-
ponents with extremely low concentrations [11,14–16]. MS has been applied often in
biological and biomedical research, especially among proteomics and metabolomics
in omics cascade. Those applications include components structural characteriza-
tion [17–19], components detection and identification [20–22], profiling of biological
samples [23–25], and qualitative and quantitative analysis [26–29].
1.3 Zero-inflated MS data
One characteristic of MS-based proteomics and metabolomics is the data frequently
contain a large proportion of zeros for many components. During the experiment
3
process, the MS instruments may experience difficulties in detecting the weak signals
of components or distinguishing the true signals from background noise, especially
for those components with low abundance [30]. Thus, the massive zero values seen
in MS data are associated with two causes. Those zero values are called point mass
values (PMVs). On one hand, if the component is absent in the sample, it is for a
biological reason, then the zero is called a biological point mass value (BPMV). On
the other hand, if the component presents in the sample but the signal is below the
detection limit (DL) for a technical reason, then the zero is called a technical point
mass value (TPMV) [31].
Due to technical limitations, the two types of zeros cannot be separated during
the experiment. This special characteristic caught statisticians’ attention. The in-
tensive zeros may cause computational difficulties and have negative impacts on the
distribution assumptions and statistical inferences based on the assumptions. Several
studies confirmed MS omics data to be missing not at random (MNAR) [32,33]. Bias
can be introduced by the non-random missingness of the data [32,34]. The challenge
here is to characterize both biological and technical PMVs appropriately during the
downstream analysis.
1.4 Statistical methods for mass spectrometry based proteomics and
metabolomics data
In this dissertation, we focus on proteomics and metabolomics. There are some
common goals in both fields, such as biomarker discovery [35, 36], disease diagnos-
tic [37, 38], disease pathway identification [39, 40], and drug discovery and develop-
ment [41–43]. In a review article, Ren et al. (2015) summarized the analysis types
and most frequently used statistical methods for metabolomics data. Their summary
table lists five types of analysis, including basic statistical testing for differential
abundance analysis, unsupervised learning for clustering and data visualization, su-
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pervised learning for classification, pathway analysis for meaningful disease pathway
identification, and time course data analysis for longitudinal studies [44]. Similar
analytical strategies can also be applied to proteomics.
The zero inflation issue we mentioned above is rarely addressed by those standard
statistical methods and advanced methods are not sufficient in this field [45–47].
One frequently applied technique to handle missing values is imputation. There are
numerous imputation methods devoted to deal with missing data. Most of them
don’t handle the MNAR data generated by MS. There are a few normalization and
imputation methods and R packages developed specially for the HTP MS data [30,48].
However, due to the complex mechanisms of the missing data, no imputation methods
can be applied in general, and using inappropriate methods could lead to inaccurate
results [49,50]. Statistical models designed explicitly tp account for missing values is
an alternative strategy [34]. Due to the inefficiency of the imputation instruments,
there is a need to develop suitable statistical methods which do not depend on current
imputation techniques for the zero-inflated MS data.
Statistical methods for Differential Abundance Analysis
One basic research interest lies in comparing different phenotypes and identifying
the possible factors that cause the difference. Within quantitative proteomics and
metabolomics, the test is often referred to as differential abundance (DA) analy-
sis. The components in different types of biological samples vary from one sample
to another. To make it simple and consistent throughout this dissertation, we use
“feature” to represent all types of components. Abundance of features from the bi-
ological samples are compared between different clinical phenotypes. DA analysis is
applied to biomarker discovery and disease risk factor identification, which offer use-
ful insights for further investigation on disease pathway, diagnostic utility, and drug
development [51–54].
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Statistical methods proposed for the zero-inflated MS omics data can be grouped
into three categories [47]. The first type of method is one-part tests. As the name
suggests, these tests consider the data from a single distribution and compute a
simple test statistic. The second type is two-part tests, which consider whether the
data come from two distributions and construct a pooled test statistic. The last type
is mixture models, which assume PMVs are a mixture of BPMVs and TPMVs and
non-PMVs follow a truncated and normalized normal distribution [47].
Zhang et al. (2009) [46,47] performed a thorough comparison among t-tests with
different ad-hoc approaches, the Tobit model, and many nonparametric tests. The
accelerated failure time (AFT) model from survival analysis was adapted by Tekwe et
al. (2012) to analyze proteomics data. They compared two-part t-test, Kolmogorov-
Smirnov test, Wilcoxon–Mann–Whitney rank-sum test, and AFT models with dif-
ferent distribution assumptions and concluded that the AFT models performed best
in DA analysis. Time to event data are known to be non-negative and censored.
Although MS omics data are not survival data, they share similar characteristics in
being non-negative and left-censored [33,34]. These statistical tests assume all PMVs
are censored when the concentration of features are below DL. Thus, they might not
work well when the data contain not only TPMVs but also BPMVs.
Many studies have been done to compare the performance of one-part and two-part
tests. Taylor and Pollard (2009) conducted a comparison among several two-part tests
including two-part t-test, two-part Wilconxon, and two-part models with likelihood
ratio test [55]. A similar comparison was done by Dakna et al. (2010) [31]. Both
studies suggested that the two-part models with likelihood ratio test outperformed the
standard two-sample tests when the missing value proportion was high. Despite the
improvement achieved by those two-part tests, they designed to separate all PMVs
completely from the continuous values, thus fail to fully account for the MNAR in
MS omics data. Therefore, they may work well for data that contain only TPMVs
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rather than data with mixed types of PMVs.
Mixture models that separate TPMVs from BPMVs were developed to address the
above issue. A mixture model based on a binomial distribution combined with a trun-
cated and normalized normal distribution was applied to proteomics data produced
by polyacrylamide gel electrophoresis for DA analysis by Wu et al. (2009) [56]. The
binomial distribution is for the probability of PMVs conditional on groups, and the
truncated and normalized normal distribution is for the continuous part. Compared
to the t-test, the mixture model maintained good performance on the DA analy-
sis for various simulation settings. Karpievitch et al. (2009) compared a mixture
model consisting of a binomial distribution and a truncated log normal distribution
to ANOVA with different ad-hoc approaches in the MS proteomics data setting [33].
They claimed that the mixture model achieved more true discoveries at any given
false discovery rate (FDR).
Taylor et al. (2013) compared the performance in DA analysis of a mixture
model to an AFT model [34]. They concluded that the mixture model was preferred
in parameter estimation while TPMVs presented in the data, especially when the
proportion of TPMVs was large. Gleiss et al. (2015) conducted a comprehensive
comparison among multiple one-part tests, two-part tests, and a similar mixture
model [47]. They confirmed the above finding. However, other models are superior
to the mixture model when the data contain no TPMVs [34, 47]. There is a need to
develop suitable and more efficient mixture models that can account for mixed types
of PMVs for the zero-inflated MS omics data.
Statistical methods for Cluster Analysis
Another research interest is cluster analysis, which aims to separate a large number
of multivariate observations into subgroups with homogeneous observations or group
similar variables together [57, 58]. Cluster analysis is important in many fields in-
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cluding biological and biomedical research. Information obtained from similarities
within clusters and dissimilarities among different clusters have many advantageous
applications, such as biomarkers identification [59] and disease diagnostics [60].
Two commonly used clustering methods for proteomics and metabolomics data
are K-means and Hierarchical clustering [44, 60, 61]. K-means clustering belongs to
partitioning algorithms as a basic cluster analysis type [62]. It is also considered to be
one of the most popular iterative descent cluster analysis methods [63]. The algorithm
starts with the initial cluster assignment and finds group means which minimize the
total cluster variance. Then each observation is reassigned into the closest cluster
mean (based on the calculated group means) to minimize the total cluster variance.
Those two steps are iterated until there are no changes in cluster assignment [63]. In
practice, K-means algorithms usually reach convergence rapidly [64]. However, the
algorithms are sensitive to the initial starting assignment and often converge at one
of the numerous local minima rather than global minimum [65].
K-means clustering with different choices of cluster numbers may return various
results, thus how to choose the cluster number is another key issue for K-means clus-
tering algorithm. In contrast to K-means, Hierarchical clustering analysis does not
need the cluster number to be specified. In addition, it is not an iterative cluster
analysis method. Therefore, the issue of convergence is not a concern for Hierar-
chical clustering. Bottom-up (agglomerative) and top-down (divisive) are two basic
strategies. The top level contains only one cluster with all objects and the bottom
level contains one cluster for each object. Bottom-up strategy is to group the two
closest clusters together at each step until reaching the top, and top-down strategy is
to divide one cluster into sub-clusters with the most dissimilarity at each step until
reaching the bottom. Therefore, each hierarchical level is associated with a unique
cluster number [63, 66]. In the omics field, Hierarchical clustering analysis is often
applied to group features rather than objects [67].
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Both K-means and Hierarchical cannot handle the situation where PMVs are a
mixture of BPMVs and TPMVs. Model-based methods with or without maximum
likelihood principle were frequently applied to various data types with different un-
derlying assumptions including multivariate Gaussian or non-Gaussian [57,66,68,69].
One key advantage of the model-based methods is the availability to adapt a variety
of distribution assumptions while the standard methods are inadequate [70]. It has
the ability to model the underlying mixture distribution in MS data. Another advan-
tage is that model-based methods often apply the EM algorithm [71]. Approximate
posterior probabilities for clustering can be calculated using estimated model param-
eters from the optimization process [72]. Meanwhile, those estimates can provide
deeper insights into the causes of different clusters. To our knowledge, the model-
based clustering algorithms are not applied often in the proteomic and metabolomic
studies.
Copyright c© Zhengyan Huang, 2019.
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Chapter 2 Improved Differential Abundance Analysis with Bayes
Shrinkage Estimation on Variance for Proteomics and Metabolomics
Data
2.1 Introduction
Background
High-throughput (HTP) data obtained from biological samples can help to under-
stand diseases’ biological mechanism, to identify prognostic and predictive biomark-
ers, and to develop better treatments [1,10]. With the emerging advanced analytical
techniques, the new “Omics” era has arrived. Thoroughly studying each omics field
and systematically combining them together could lead to a more comprehensive
understanding of systems biology [6]. Appropriately analyzing the voluminous and
comprehensive information obtained through those analytical instruments can lead
to better biomarker identification and more complete understanding of biological ef-
fects [1, 14].
In recent years, proteomics and metabolomics have become valuable tools to inves-
tigate molecular and cellular biology [1,10,73]. Mass spectrometry (MS) is widely used
for proteomic and metabolomic profiling of biological samples. One frequently seen
characteristic of the high-throughput (HTP) data produced by MS is that the data
are zero-inflated. Those zero values are called point mass values (PMVs). According
to the causes, the PMVs can be further classified into biological PMVs (BPMVs),
where the compound is absent from the sample, and technical PMVs (TPMVs), where
the compound is present but its abundance is below the detection limit (DL). Due
to the technical limitations, the two types of point mass values(PMVs) cannot be
separated during the experiment (Figure 2.1). Data used to generate Figure 2.1 are
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from human urinary proteome database (HUPD) [74]. We selected one peptide to
show the zero-inflated nature of the data. We will describe the database later in the
applied data analysis (section 2.4). Because there is often a large fraction of PMVs
in an MS dataset, statistical analyses need to account for the PMVs, preferably to
further separate BPMVs and TPMVs, to ensure unbiased and efficient inference.
Figure 2.1: Distribution of Collagen alpha-1(I) chain. Among all 1865 observations,
there are 720 PMVs.
Identifying differentially abundant features between phenotypic groups is the cen-
tral goal for many proteomic and metabolomic studies. A number of statistical meth-
ods have been proposed for differential abundance analysis based on zero-inflated MS
data. Generally, there are three types of methods [47]. The first type is one-part tests.
Those methods either exclude all PMVs or impute zeros to non-zero values based on
different strategies, then apply the statistical tests. For example, an adaptive t-test
imputes PMVs with certain non-zero values and perform a two-sample t-test on im-
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puted data. For the methods using t-tests, it is hard to justify the approximately
normal distribution. The second type is two-part tests, which consider the data as a
mixture distribution of PMVs and non-PMVs and use a separate model for each part.
In general, the first part is to compare the proportion of PMVs and the second part
is to compare the continuous values. These two independent test statistics are then
combined to calculate a pooled test statistic. One limitation of the aforementioned
methods is that they do not distinguish TPMVs and BPMVs. A third type of method
has been developed to address this problem.
The mixture model design
To address the above problem, a new differential abundance analysis method was
proposed by Taylor et al. (2013) [34], as well as Gleiss et al. (2015) [47], based
on similar mixture models. The mixture models consider PMVs as a mixture of
TPMVs and BPMVs. The TPMVs are treated as left-censored data from a normal
distribution. The BPMVs are considered as a point mass at zero. A likelihood ratio
test is proposed to test whether both the mean parameter of the normal distribution
and the point mass at zero are the same between experimental groups. For a single
feature k, the density for Xij (the i
th observation in group j) is:
f(Xij|pj, µj, σj) =

pj + (1− pj)Φ(λ|µj, σ2j ), if PMVs
(1− pj)φ(log(Xij)|µj, σ2j ), if non-PMVs
(2.1)
where pj is the proportion of BPMVs, µj is the mean parameter, and σj is the
standard deviation for group j, λ is the detection limit (same for different groups), and
Φ and φ are the cumulative distribution and density function of a normal distribution,
respectively. To simplify the above function, we suppress the notation k for the
feature.
Taylor et al. (2013) compared the performance of the mixture model to an accel-
erated failure time (AFT) model and concluded that the mixture model was preferred
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in parameter estimation when TPMVs presented in the data, especially when the pro-
portion of TPMVs was large. Gleiss et al. (2015) compared the mixture model with
eight one-part or two-part tests and confirmed the above finding. However, the au-
thors concluded that some other models were superior to the mixture model while no
BPMVs or no TPMVs presented [34,47]. We noticed that in both papers, the authors
applied fixed parameters in their simulations. Among all scenarios, the largest total
zero proportion from both BPMVs and TPMVs combined was only 75%. They also
applied different restrictions to the applied data analyses, which significantly reduced
the number of features included in the final analysis datasets. The motivating human
urinary proteome database (HUPD) used by Gleiss et al. (2015) contains over 5,600
peptides. They comprised the analysis dataset to include 25 chronic kidney disease
and 25 control patients and restricted the PMV proportion to be below 70%. This
cut down the number of peptides in their final analysis dataset to be only 787. In
reality, MS data often has tons of features with larger PMV proportion. The HUPD
dataset contains a large number of peptides with PMV proportion over 90% for many
disease conditions.
To check the performance of the mixture models on data with larger PMV pro-
portions, we applied the method on a real-world dataset obtained from HUPD. We
required at least three non-PMVs from two groups combined, and at least one PMV
and one non-PMV for each group to make sure the algorithm could be processed. We
will refer the two restrictions as the feature inclusion criteria throughout this study.
We compared the R code offered in both publications and found the code from Taylor
et al. (2015) has fewer convergence problems while running. Therefore, their code
was used for the mixture model. Since they didn’t name the method, we will use
their initials and refer their model as “TLK” throughout this dissertation.
Later, we found although TLK is appealing in distinguishing TPMVs and BPMVs
and therefore in providing better characterization of MS data, parameter estimation,
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especially on variance, from the mixture model can be unstable in presence of large
portion (over 90%) of zero values (Figure 2.2). Figure 2.2 figure presents the variance
estimation results from a single simulation. Panel a and b are for features with over
90% PMVs and panel c and d are for features with less than 90% PMVs. The figure
clearly shows that when PMV proportions are large, the variance can be overestimated
(panel a) or underestimated (panel b). On one hand, overestimation of the variance
may lead to false negative results. On the other hand, underestimation of the variance
may lead to false positive results.
Figure 2.2: Estimated versus true variances of TLK simulation result with 100 ob-
servation per group. Panel a and b are for features with over 90% PMVs on full
and reduced scales, panel c and d are for features with less than 90% PMVs on full
and reduced scales. Red lines show where the estimated variances equal to the true
variances.
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Bayes shrinkage estimator
MS data obtained for proteomic and metabolomic profiles also inherit a massive
multiple testing problem because the biological samples used in the experiment always
contain numerous features. This problem can be solved by many well established
methods, which is not a concern in this study. Meanwhile, the parallel nature of the
experiment makes it possible to borrow information across features, which can assist
in inference about individual ones [75]. Bayes and empirical Bayes methods with
shrinkage on key estimators have been shown to provide a robust estimation of model
parameters, especially the variance parameter, for microarray [75], RNAseq [76–78],
and NanoString data [79]. Although it maybe biased, the Bayes shrinkage approach
can result in more stable estimates.
We expect that by adapting a Bayes shrinkage estimation on variance, the unstable
issue presented in the original mixture model can be solved. Thus, the false positive
and false negative results will be reduced, and the overall performance on differential
abundance analysis can be improved.
2.2 Proposed method: DASEV
We here propose a new method called Differential Abundance Analysis with Bayes
Shrinkage Estimation of Variance (DASEV). It uses an empirical Bayes shrinkage
method to more robustly estimate the variance and enhance the accuracy of differ-
ential abundance analysis. To our knowledge, this research is the first to apply such
a method in MS studies. We demonstrate the improvement achieved by our method
through simulation studies, as well as real data applications.
The Model
We focus on two-group comparisons and refer to the two groups as control (group
1) and case (group 2) groups. We assume that the HTP MS data for a proteomic
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or metabolomic feature contain two parts, PMVs and non-PMVs, where PMVs are
a mixture of BPMVs and TPMVs. We further assume that non-PMVs follow a log
normal distribution truncated at the DL, where the truncation leads to TPMVs.
Under those assumptions, for a single feature k, the density of the ith observation
in group j, Xijk, follows a mixture distribution [34, 47] with the following density
function
f(Xijk|pjk, µjk, σk) =

pjk + (1− pjk)Φ((λk − µjk)/σ2k), if PMVs
(1− pjk)φ((log(Xijk)− µjk)/σ2k), if non-PMVs
(2.2)
where pjk is the proportion of BPMVs and µjk is the mean parameter for group j
(j = 1, 2) and feature k, σk is the standard deviation and λk is the detection limit
for feature k, and Φ and φ are cumulative distribution and density functions of a
standard normal distribution, respectively. Based on equation (2.2), the non-PMV
observations follow a truncated normal distribution
f(Xijk|Xijk > 0, µjk, σk) = φ((log(Xijk)− µjk)/σ
2
k)
σk[1− Φ((λk − µjk)/σ2k)]
(2.3)
In presence of large fraction of PMVs, parameter estimation based on model (2.2)
can be unstable (Figure 2.2). In order to improve the estimation, we introduce a prior
distribution for σ2k across all features. Specifically, we consider an inverse-gamma
distribution (Figure A2.1) with shape parameter d0/2 and scale parameter d0s
2
0/2.
σ2k ∼
(d0s20
2
) d0
2 σ
2
(
−1− d0
2
)
k
Γ(d0
2
)
exp
(
− d0s
2
0
2σ2k
)
(2.4)
This prior distribution allows us to borrow information across the ensemble of
features so that more stable variance estimation can be obtained. The hyperparam-
eters, d0 and s0, are empirically determined from the data as described in the next
subsection.
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Determining hyperparameters
We first obtain an initial estimate of σk as the value that maximizes the likelihood
for non-PMVs, i.e. Π2j=1Π
nj
i=1f(Xijk|Xijk > 0, µjk, σk), where µjk is set as the sample
mean of non-PMVs in group j, nj is the number of observations in group j and the
DL is set as the minimal log-transformed non-PMV observation minus 0.1. Note that
this initial estimate of σk is only used for the calculation of hyperparameters. Once
the hyperparameters are determined, a more robust estimate of σk is obtained as
described in the next subsection. Let m and v be the sample mean and variance for
the initial estimate of σk across features, respectively. Based on the inverse gamma
distribution and using the method of moments, the d0 and s0 are calculated as follows
d0 =
2m2
v
+ 4 and s0 =
√
m(d0 − 2)
d0
(2.5)
In order to robustly estimate d0 and s0, we restrict features included in this calculation
to be those with at least 10 non-PMV observations from the two groups combined.
However, we also require that at least 30 features to be included. If total number of
features is less than 30 after applying the 10 non-PMVs restriction, we use the top
30 features with the smallest PMV proportion while combining the two groups.
Model Parameter estimation
We use an iterative procedure to obtain our estimates of θk = (µ1, µ2, p1, p2)
T and σk.
For a given σk, θk is estimated by maximizing the likelihood
L(θk|σk) =
2∏
j=1
{
nj∏
i=1
f(Xijk|pjk, µjk, σk)
}
(2.6)
where nj is the number of observations in group j. For a given θk, σk is estimated by
maximizing the posterior
p(σ2k|data) ∝
2∏
j=1
{
nj∏
i=1
f(Xijk|pjk, µjk, σk)
}
×
(d0s20
2
) d0
2 σ
2
(
−1− d0
2
)
k
Γ(d0
2
)
exp
(
− d0s
2
0
2σ2k
)
(2.7)
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We first plug in the initial estimate of σk into equation (2.7) to find the maximum
likelhood estimate of θk, θˆk. The θˆk is then plugged into equation (2.6) to obtain the
posterior mode, σˆk. By iteratively updating θˆk and σˆk until convergence, we obtain
estimates of θk and σk.
Hypothesis testing
We suppress k for features in the following functions to make them easier to read.
Our method allows examining the following three hypotheses for each feature:
HM0 : µ1 = µ2 = µ vs H
M
A : µ1 6= µ2
which tests if the group means are different.
HP0 : p1 = p2 = p vs H
P
A : p1 6= p2
which tests if the BPMV proportions are different.
HB0 : µ1 = µ2 = µ and p1 = p2 = p vs H
B
A : µ1 6= µ2 and/or p1 6= p2
which tests if the group means or the BPMV proportions are different. A likelihood
ratio test statistic is used to test each of the three hypotheses. Specially,
For testing HM0 :
TM = log
{∏2
j=1
[∏nj
i=1 f(Xij|p1, p2, µ1, µ2, σ)
]∏2
j=1
[∏nj
i=1 f(Xij|p1, p2, µ, σ)
] } (2.8)
For testing HP0 :
TP = log
{∏2
j=1
[∏nj
i=1 f(Xij|p1, p2, µ1, µ2, σ)
]∏2
j=1
[∏nj
i=1 f(Xij|p, µ1, µ2, σ)
] } (2.9)
For testing HB0 :
TB = log
{∏2
j=1
[∏nj
i=1 f(Xij|p1, p2, µ1, µ2, σ)
]∏2
j=1
[∏nj
i=1 f(Xij|p, µ, σ)
] } (2.10)
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A p-value is obtained based on a χ2 distribution with one degree (for testing HM0
and HP0 ) or two degrees (for testing H
B
0 ) of freedom. The Benjamini and Hochberg
procedure [80] is used to control the false discovery rate (FDR).
In this study, we focus on testing if the group means are different (HM0 ) or if the
BPMV proportions are different (HP0 ). The proposed method is compared with TLK
via simulations and applied data analysis in section 2.3 and section 2.4.
2.3 Simulation studies
To get a comprehensive evaluation on the performance of DASEV, and to compare
with TLK, we used a combination of simulations and real data. For TLK, the al-
gorithm only returns a p-value for each feature, but does not provide a procedure
for multiple comparisons adjustment. To allow a fair comparison, we used the Ben-
jamini–Hochberg procedure to control the FDR, same as what is used in DASEV.
Simulation settings
To mimic a real-world data, we based our simulation on real data obtained from
HUPD. We applied the feature inclusion criteria, and the final dataset contains 5,270
peptides. We estimated feature-wise raw mean of non-PMVs, zero proportion, DL,
and variance. These values were used to set parameters for our simulations. Specifi-
cally, each simulated dataset contained 5,000 features. The abundance level of each
feature was simulated based on the mixture distribution in equation (2.2), where the
model parameter values were randomly re-sampled from the estimates in the HUPD
data.
We considered two differential abundance scenarios. The first scenario aims
to evaluate the methods’ performance in identifying the mean differences between
groups. We randomly selected 10% of features to have a 2-fold difference in the
mean abundance comparing case and control groups, with 5% of features having
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higher abundance, and another 5% having lower abundance in the case group. The
second scenario aims to evaluate methods’ performance in identifying BPMV pro-
portion difference between groups. We randomly selected 10% of features to have an
odds ratio=2 in the proportion of BPMVs comparing case and control groups, with
5% features having higher BPMV proportion and another 5% having lower BPMV
proportion in the case group.
We present the results from the first scenario in this subsection. The results
from the second scenario are provided in Supplementary Materials. We considered
a sample size of 100 or 200 per group, and replicated the simulation 100 times for
each sample size. For each simulated dataset, we filtered out features based on the
inclusion criteria before performing the analysis.
Simulation results
The main focus is to improve the performance in detecting the differentially abundant
features, which largely depends on parameter estimation. To demonstrate the im-
provements we obtained for the proposed method in the differential abundance (DA)
analysis, we would like to show the parameter estimation first. Figure 2.3 presents
the feature variance estimation from DASEV and TLK based on a simulated dataset
with 100 observations per group. On one side, TLK substantially overestimated the
variance for a subset of features (panel a). On the other side, it substantially under-
estimated the variance for another subset of features (panel c). Some of the variance
estimates are very close to zero. A majority of those extreme estimations were for
features with over 90% PMVs. In contrast, DASEV provided a much more robust
estimation of the feature variance. It seldom returned extremely large (panel b) nor
small (panel d) variance estimates.
The unstable estimate of variance based on TLK also affected the estimation of
mean and BPMV proportion. As shown in Figure 2.4, the estimated mean (panel
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Figure 2.3: Estimated versus true variance of DASEV and TLK, 100 observations
per group. Panel a and b are TLK and DASEV on full scale, and panel c and d are
TLK and DASEV on reduced scale with estimated variances range from 0 to 2. Red
lines show where the estimated variances equal to the true variances.
a) and BPMV proportion (panel c) were far away from true values for a subset
of features, especially features with large fractions of PMVs. In contrast, DASEV
yielded much fewer features with deviated mean and BPMV proportion estimates.
In this simulation, TLK returned 231 features with mean values estimated to be below
DL. The number of such features for DASEV was 40. We also confirmed this finding
among other simulations; DASEV always resulted in much less problematic features
than TLK.
We next compared the performance of DASEV and TLK for identifying differ-
entially abundant features comparing the two groups. With better parameter esti-
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Figure 2.4: Comparisons of estimated parameters for mean and BPMV proportion in
the control group from DASEV and TLK with 100 observations per group. Panel a
and c are for TLK, and panel b and d are for DASEV.
mation, we also expected DASEV to outperform TLK also in the DA analysis. One
important task in this endeavor is to rank features based on their likelihood of being
differentially abundant. Figure2.5 shows the top 150 features ranked by TLK (panel
a) and DASEV (panel b) based on the single simulated dataset. Within the top
features identified by TLK, 41 were false positives. Most of those features had large
fractions of PMVs. Their estimated variances tended to be small, some were even
close to zero. Therefore, TLK assigned favorable rankings to them even though some
of them had vary small fold changes.
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To get a more general understanding of the improvement, we plotted the true
positive rate (TPR) as a function of the number of selected top-ranked features based
on the average of 100 simulations for sample size 100 (panel c). For DASEV, as
expected, the TPR was one for the very top ranked features and decreased as more
features were included. The curve based on DASEV was higher than that based
on TLK, indicating DASEV was able to rank more true positive features to the
top compared to TLK. Interestingly, the curve based on TLK was not monotone,
indicating that even the very top features selected by TLK contained false positives.
In addition, we compared numbers of true positives (TPs) and false positives (FPs)
identified by DASEV and TLK for a given FDR threshold of 1%, 5%, or 10%. Panel
d presents the results averaged over 100 simulations for 100 observations per group.
Compared to TLK, DASEV identified a similar number of TPs but much fewer FPs.
For example, at 1% FDR threshold, DASEV identified an average of 62 TPs and
only 2 FPs. In contrast, TLK identified an average of 63 TPs but 11 FPs. For
both methods, the observed FDR among the identified features were higher than the
desired FDR threshold value. But the observed FDR from DASEV was much lower
than that from TLK.
As we increased the sample size to 200 observations per group, the overall perfor-
mance for both methods got improved. But, TLK still had the issue with unstable
estimation on variance, mean, and BPMV proportions (supplementary Figures A2.2
and A2.3). Less FPs were identified among the top 150 ranked features by both
methods. TPR increased for both methods, with the TPR based on DASEV still
higher than that based on TLK. The curve based on TLK was still not monotone,
with false positives selected in the very top features. In addition, the observed FDR
became closer to the FDR threshold value with larger sample sizes. The observed
FDR from DASEV was still much lower than that from TLK (supplementary Figure
A2.4).
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Figure 2.5: Aggregated results for simulations with 100 observations per group. Panel
a and b are log fold change in estimated mean versus variance in a single simulation
for TLK and DASEV, respectively. Filled points are for features with PMVs larger
than 90%. Panel c is the average TPR for top 150 features on 100 simulations. Panel
d is the average counts (with rate) of true and false positive discoveries at three
reported FDR points on 100 simulations.
For simulations with difference in BPMV proportions, we obtained similar results.
The parameter estimation results were identical to those for testing difference in mean
abundance. Therefore, we will not discuss them again. The change to mention was
that the true FDR for DASEV was smaller than the threshold FDR. However, for
TLK, the true FDR was still larger than the threshold FDR. With the sample size
increased to 200 observations per group, the true FDR for both methods got closer
to the threshold FDR. DASEV was able to identify more TPs and still held lower
FDR than TLK. Please check the supplementary Figure A2.5 for those results.
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2.4 Real data analysis
To further demonstrate the proposed method, we also compared it to TLK using real-
world data analysis. We conducted two studies. The first is a sub-sampling analysis
on the proteomics database (HUPD) used by Taylor et al. (2015), and the second
is analysis on a metabolomics dataset for lung cancer patients provided by Markey
Cancer Center, University of Kentucky [81].
Real data sub-sampling analysis - HUPD proteomics
Human urinary proteome database (HUPD) data was obtained from urine samples
processed by capillary electrophoresis-mass spectrometry (CE-MS). The database
contains urine samples from 13,027 patients with 47 different pre-selected patho-
physiological conditions [74]. For method demonstration, we focused on identifying
differentially abundant peptide features comparing 362 benign prostatic hyperplasia
patients and 1,503 healthy controls. After applying the previously described feature
inclusion criteria, we obtained a total of 5,270 peptides for our analysis. The average
PMV proportion for this data is over 80%.
We applied both DASEV and TLK to the analysis dataset. Under the threshold
of FDR ≤ 1%, DASEV identified 968 and TLK identified 1017 significant peptides
for testing the hypothesis HM0 . Within these features, 960 were identified by both
DASEV and TLK. As the ground truth for a real dataset is unknown, we performed
a sub-sampling analysis to investigate the concordance between full data analysis and
subsample analysis. Specifically, we assumed the 960 features commonly identified
by both methods from the full dataset as “positive” features. Likewise, we obtained
2,727 features with FDR q-value ≥ 0.3 and assumed them as “negative” features.
We randomly selected 100 or 200 observations each of the benign prostatic hy-
perplasia and healthy control groups to form a subsample. We applied DASEV and
TLK to the subsample to evaluate whether they could recover the “positive” and
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“negative” features obtained from the full dataset. Results from sub-sampling 100
observations per group were shown in Figure 2.6. Results from sub-sampling 200
observations per group were provided in supplementary Figure A2.6. Among the 150
top-ranked features, DASEV identified 11 more “true positive” features than TLK
(panel a and b). Similar to our findings from simulation studies, the variance esti-
mates based on TLK were very close to zero for many features, which explained the
higher number of “false positive” features in TLK results. In addition, the “true pos-
itive rate” based on DASEV was always about 10% higher than that based on TLK
at any given number of top ranked features (panel c). Furthermore, at a given FDR
threshold, DASEV identified similar numbers of “true positive” features yet fewer
“false positive” features compared to TLK (panel d). All these analyses suggested
that the sub-sampling analysis results from DASEV had a higher concordance with
the full data analysis results.
Figure 2.6 shows the results from the sub-sampling analysis with 100 observa-
tions per group. Panel a and b are from one single analysis for TLK and DASEV,
respectively, and panel c and d are for the average over 100 replications. Similarly to
the simulation results, the small variance issue exists in TLK (panel a). Among the
top 150 features selected, DASEV identified 11 more differentially abundant peptides
compared to TLK (panels a and b). The TPR for DASEV is about 10% higher than
the rate for TLK consistently at any number of top ranked features (Panel c). Sim-
ilar to the results from our simulations, DASEV maintained better FDR than TLK
(Panel d).
The results are similar for the sub-sampling analysis with 200 observations per
group. With the increase in sample size, the true FDR for DASEV got closer to
the threshold FDR. However, the true FDR for TLK was still much higher than the
threshold FDR. Please check the supplementary Figure A2.6 for those results.
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Figure 2.6: Aggregated results for sub-sampling analysis with 100 observations per
group. Panel a and b are log fold change in estimated mean versus variance in a
single analysis for TLK and DASEV, respectively. Filled points are for features with
PMVs larger than 90%. Panel c is the average TPR for top 150 features on 100
sub-sampling analyses. Panel d is the average counts (with rate) of true and false
positive discoveries at three reported FDR points on 100 sub-sampling analyses.
Real data analysis - metabolomics
We also analyzed a non-small cell lung cancer exosomal lipids profiling dataset re-
ported by Fan et al. (2018) [81]. We focused on identifying differentially abundant
lipid features between 44 early stage and 47 late stage lung cancer patients. After
applying the feature inclusion criteria, 101 features were considered in our analysis.
The molecular formulae of the lipids were determined by ultrahigh resolution accurate
mass spectrometry as previously described [81].
We applied both DASEV and TLK to the dataset and focused on testing the
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hypothesis HM0 . Each method returned 11 significant lipids at FDR ≤ 10%. Among
them, eight features were identified by both methods. Figure 2.7 panel a shows
variance estimates for 3 lipids detected only by TLK. The TLK estimated variances
were close to zero for all three lipids, which was the reason that TLK called them
as significant. In contrast, the DASEV estimated variances were larger, therefore
these features were not top-ranked by DASEV. Panel b compares variances estimates
between TLK and DASEV. The range of estimated variances based on DASEV was
much narrower than that based on TLK. There were no extremely large or small vari-
ance estimates based on DASEV. We particularly investigated the variance estimates
for the 3 features detected only by DASEV. For two of these features, TLK returned
large estimated variances, and thus failed to identify them. For the rest one feature,
C52H76O6, TLK and DASEV gave similar variance estimate. This feature ranked
#12 in TLK with an FDR q-value of 0.1278, which barely missed the FDR threshold.
One reason was that TLK ranked the three features with underestimated variances
before C52H76O6, and therefore moved C52H76O6 above the FDR threshold.
Using the program PREMISE [82], these features can be assigned to lipidic com-
ponents as shown in Table 2.1. The lipids are dominated by triglycerides and glyc-
erophospholipids. Triglycerides are typically storage lipids. However, some of the
acyl chains of the TAGs are polyunsaturated, which can be hydrolyzed to bioactive
lipids (diacylglycerols and the fatty acid). Studies have shown fatty acid biosyn-
thetic pathways can be molecular targets for cancer therapy, including lung can-
cer [83]. Glycerophospholipids and their lyso forms are seen to be differentially abun-
dant in the blood of cancer patients [84]. Both methods identified a ceramides lipid
(C30H58N1O6P1), which further belongs to the sphingolipids. In addition, DASEV
identified one more sphingolipids lipid (C35H69N2O6P1). Sphingolipids are impli-
cated in important cell signaling processes and are known to have regulatory roles in
tumour growth, including lung cancer [85,86].
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Figure 2.7: Metabolomics data analysis results. Panel a is log fold change in esti-
mated mean versus variance for three features identified as differentially abundant
only by TLK. Blue points show the results for TLK. The corresponding results for
DASEV are matched by different shaped points in red. Panel b is comparison of
variance estimation between two method. Red points are for three features identified
as differentially abundant only by DASEV.
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Table 2.1: Lipid information for features identified in the DA analysis by DASEV and TLK. * Features identified by both
DASEV and TLK. D Features identified only by DASEV. L Features identified only by TLK.
Formula Lipid group Lipid class Acyl Unsat Number of DASEV TLK
Chain sites carbons q-Value q-Value
C56H102O6* Triacylglycerols TAG 53 3 56 0.0486 0.0103
C18H34N1O9P1* Lysoglycerophospholipids LysoPS 12 1 18 0.0896 0.0475
C30H58N1O6P1* Ceramides Cer-1P 30 2 30 0.0896 0.0103
C42H84N1O8P* Glycerophospholipids PC 34 0 42 0.0896 0.0324
C44H84N1O8P1* Glycerophospholipids PC 36 2 44 0.0896 0.0306
C44H82N1O8P1* Glycerophospholipids PC 36 3 44 0.0972 0.0586
C44H88N1O8P1* Glycerophospholipids PC 36 0 44 0.0972 0.0103
C66H106O6* Triacylglycerols TAG 63 11 66 0.0972 0.0324
C35H69N2O6P1D Sphingolipids SM 30 2 35 0.0972 0.1617
C52H76O6D Triacylglycerols TAG 49 12 52 0.0972 0.1278
C55H82O6D Triacylglycerols TAG 52 12 55 0.0976 0.1617
C61H104O6L Triacylglycerols TAG 58 7 61 0.3308 0.0013
C45H82N1O8P1L Glycerophospholipids PE 40 4 45 0.3308 0.0311
C61H112O6L Triacylglycerols TAG 58 3 61 0.3305 0.0324
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2.5 Discussion
This chapter aims to offer an effective differential abundance analysis method for
handling the zero-inflated proteomics and metabolomics data. We compared our
proposed method with TLK using simulation studies and real data analysis. We
obtained clear improvements in differential abundance analysis by applying the Bayes
shrinkage estimation on variance.
In our simulation study, we generated data based on parameters designed to mimic
real-world scenarios rather than parameters with fixed values. Taylor et al. (2013)
didn’t consider the variability across all features in their simulations. They set same
variance, mean, BPMV proportion, and detection limit for all features. In addition,
as we mentioned in the introduction, they limited the maximum PMV proportion to
be 75% by applying the fixed parameters. Although they did an extensive simulation
study with many scenarios, none of them well represent real data. We took the
variability into account and allowed all those four parameters to be different for each
feature in our simulation.
We set the sample size to be relatively 100 and 200 per group in our simulation.
Even the sample sizes are considered to be large, however, with huge PMV proportion
we still obtained many features with less than 3 non-PMV observations with two
groups combined. This was caused by the extremely large values of PMV proportion
from the real dataset. Although we did not indeed apply a small sample size setting,
we only required at least 3 non-PMV observations compared two groups for a feature
to be included in the analysis. In this way, we were able to keep the features with
high PMV proportions (up to 99%) and to demonstrate the method performance for
those features.
When PMV proportion is extremely large, the estimations on variance can be
very unstable. In order to ensure we can capture the variability but to minimize the
impact from those unstable estimations, we applied two restrictions on the variance
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prior distribution as we mentioned in the method section 2.2. Those restrictions can
be changed to accommodate extended situations such as a small sample size and a
small number of features.
From the above results, we can see DASEV returns better and more stable esti-
mations on variance especially while the PMV proportion is large. Thus, the mean
and BPMV proportion estimates are more accurate compared to those obtained by
TLK. Therefore DASEV rarely returns false positive discoveries caused by extremely
small variance estimation. Although DASEV is a little conservative in identifying
features compared to TLK, it achieves much better control on FDR.
Non-small cell lung cancer is relatively insensitive to regular chemotherapy, and
effective target therapies can help the survival of those patients [87]. At our selected
FDR (0.1), DASEV identified C35H69N2O6P1, which belongs to the sphingolipids
group. TLK failed to discover this lipid. Sphingolipids and their downstream targets
have regulatory roles in tumour growth and respond to different kinds of therapies,
including lung cancer [85, 86]. In the dataset we used for the studies, early stage
patients had higher abundance of C35H69N2O6P1 than late stage patients did. Many
other lipids identified in the metabolomics data analysis belong to the lipid groups
which are also clinically significant in cancer progression. Further investigation can
be done regarding their roles in cancer clinical implications.
There are some limitations. In our study, we assume a log normal distribution
for the continuous part, and we did not apply any other distribution. In addition, we
only test the proposed method for the simple two group comparison without other
covariates. Furthermore, we did not consider different variances between the two
groups. Future work can be done to generalize DASEV to allow multiple groups,
other underlying distributions, different variances among groups, and other factors
and their interactions.
In conclusion, compared to TLK, DASEV is more efficient in identifying differ-
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entially abundant features. Thus, it can be used as an alternative in differential
abundance analysis and the identification of potential biomarkers and therapeutic
agents.
Copyright c© Zhengyan Huang, 2019.
33
Chapter 3 Cluster Analysis for zero-inflated MS proteomics and
metabolomics data
3.1 Introduction
Background
With the revolution in “Omics” studies, proteomic and metabolomic studies have
become valuable tools to investigate molecular and cellular biology [1, 10]. Different
strategies associated with Mass spectrometer (MS) technology have been developed
to promote its usage. Appropriately analyzing the voluminous and comprehensive
high-throughput (HTP) data obtained through MS technology can lead to a more
complete understanding of biological effects [1, 14].
Cluster analysis has extensive applications in many fields including biological and
biomedical research. Cluster analysis aims to separate a large number of multi-
variate observations into subgroups with homogeneous observations or group similar
variables together [57, 58]. One research interest in the cluster analysis setting is
to divide observations into groups with similar clinical or disease conditions. Infor-
mation obtained from similarities within clusters and dissimilarities among different
clusters can be applied to biomarker discovery, disease diagnostic, and etc. [59, 60].
Currently, only two types of clustering algorithms are commonly used for proteomics
and metabolomics data: K-means clustering and Hierarchical clustering [44,60,61].
K-means and Hierarchical clustering
One of the basic cluster analysis types is partitioning algorithms, and K-means be-
longs to this group [62]. K-means can also be classified into iterative descent cluster
analysis methods, and it is considered to be the most popular one [63]. One advan-
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tage of K-means is that the algorithms usually converge quickly [64]. Therefore, it
is widely applied to large datasets. How to choose the the number of clusters is a
key issue. Different cluster numbers may return contradictory results. This is not a
concern in the scope of this dissertation. The concern we have is that the algorithms
often converge at one of the numerous local minima rather than the global one since
it is sensitive to the initial starting assignment [65].
In contrast to K-means, Hierarchical clustering analysis is not an iterative cluster
analysis method. Therefore, convergence is not an issue. In addition, no cluster
number is needed for the algorithms. Two strategies for Hierarchical clustering are
agglomerative (bottom-up) and divisive (top-down). The top level contains only
one cluster with all observations, and the bottom level contains one cluster for each
observation. On one hand, starting from the bottom, the agglomerative strategy
groups the two closest clusters together at each step until reaching a single cluster
at the top. On the other hand, the divisive strategy divides one cluster into sub-
clusters with the most dissimilarity at each step from the top level until reaching the
bottom. Each step returns a hierarchical level that associates with a unique cluster
number [63, 66]. Hierarchical clustering analysis has been applied to group features
rather than observations in the proteomics and metabolomics fields [67]. Both K-
means and Hierarchical cannot handle the situation where PMVs are a mixture of
BPMVs and TPMVs.
Model-based clustering
There are also other types of algorithms for cluster analysis. In this chapter, we focus
on model-based clustering analysis. Model-based methods with or without maximum
likelihood principles were frequently applied to various data types with different un-
derlying assumptions including multivariate Gaussian or non-Gaussian [57,66,68,69].
One key advantage of the model-based methods is the availability to adapt a va-
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riety of distribution assumptions when the standard methods are inadequate [70].
It is capable of adapting the underlying mixture distribution of the MS data. An-
other advantage is that model-based methods often apply the EM algorithm [71].
Approximate posterior probabilities for clustering can be calculated using estimated
model parameters from the optimization process [72]. Meanwhile, those estimates
can provide deeper insights into the causes of different clusters. To our knowledge,
the model-based clustering algorithms have not been frequently applied in proteomic
and metabolomic studies.
Assuming X comes from a parametric mixture distribution, which is finite with
J groups, and for all x ⊂ X, the density is written as:
f(x|Θ) =
J∑
j=1
pijfj(x|θj) (3.1)
where pij > 0 are the mixing proportions for group j (
∑J
j=1 pij = 1), fj is the density
for jth group, and Θ = (pi1, θ1, ..., pij, θj) is the parameter vector. Usually, we assume
that observations in all groups share the same density. Therefore, for all groups,
fj(x|θj) = f(x|θj). Consider we have n observations, the likelihood can be written
as,
L(Θ|x) =
n∏
i=1
J∑
j=1
pijf(xi|θj) (3.2)
Let zij denote the group membership of i
th observation, the predicted groups are
given by the posterior probabilities with estimated parameters from equation (3.2).
zˆij =
pˆijf(xi|θˆj)∑J
h=1 pˆihf(xi|θˆh)
(3.3)
The final group membership is defined as the group with the highest probability.
j = arg max
h
{zˆih}
When needed, the EM algorithm can be applied to compute maximum-likelihood
estimates [69, 71]. Equation (3.3) is the expectation step and equation (3.2) is the
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maximization step for the EM algorithm. Usually, the two steps are repeated until
the specified stopping rules are satisfied.
3.2 Proposed method: DASEV cluster analysis
As demonstrated in Chapter 2, we achieved great performance in estimating parame-
ters using DASEV. We are motivated to extend it for clustering purposes. We expect
our model-based method will outperform K-means and Hierarchical clustering meth-
ods. Since it is an extension from DASEV, we call the cluster method DASEV.C.
The Model
For the scope of this dissertation, we only consider two-group clustering analysis
(j = 1, 2). We assume that the data contains two parts, PMVs and non-PMVs.
PMVs can contain a mixture type of BPMVs and TPMVs. We also assume that
non-PMVs follow a truncated log normal distribution, and the variance is the same
for both groups. The density of the ith observation for feature k is,
f(Xik|pi1, p1k, µ1k, pi2, p2k, µ2k, σk) =
∑2
j=1 pij
[
{pjk + (1− pjk)Φ((λk − µjk)/σ2k)}1−dik
× {(1− pjk)φ((log(Xik)− µjk)/σ2k)}dik ] (3.4)
where pij > 0 are the mixing proportions for group j (
∑2
j=1 pij = 1 ), dik is 0 if
Xijk is PMV and 1 if Xijk is non-PMV, pjk is the proportion of BPMVs and µjk is the
mean parameter for group j,σk is the standard deviation, λk is the detection limit,
and Φ and φ are cumulative distribution and density functions of a standard normal
distribution, respectively.
In presence of large fraction of PMVs, parameter estimation based on model (3.4)
can be unstable. In order to improve the estimation, we introduce a prior distribution
for σ2k across all features. Specifically, we consider an inverse-gamma distribution with
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shape parameter d0/2 and scale parameter d0s
2
0/2.
σ2k ∼
(d0s20
2
) d0
2 σ
2
(
−1− d0
2
)
k
Γ(d0
2
)
exp
(
− d0s
2
0
2σ2k
)
(3.5)
This prior distribution allows us to borrow information across the ensemble of
features so that more stable variance estimation can be obtained. The hyperparam-
eters, d0 and s0, are empirically determined from the data as described in the next
subsection.
Determining hyperparameters
Observations are unlabeled in cluster analysis, thus to get a starting point, we
randomly assign each observation to group 1 or group 2. We first obtain an ini-
tial estimate of σk as the value that maximizes the likelihood for non-PMVs, i.e.
Π2j=1Π
njk
i=1f(Xijk|Xijk > 0, µjk, σk), where µjk is set as the sample mean of non-PMVs
in group j, nj is the number of observations in group j and the DL is set as the mini-
mal log-transformed non-PMV observation minus 0.1. Note that this initial estimate
of σk is only used for the calculation of hyperparameters. Once the hyperparameters
are determined, a more robust estimate of σk is obtained as described in the next
subsection. Let m and v be the sample mean and variance for the initial estimate of
σk across features, respectively. Based on the inverse gamma distribution and using
the method of moments, the d0 and s0 are calculated as follows
d0 =
2m2
v
+ 4 and s0 =
√
m(d0 − 2)
d0
In order to robustly estimate d0 and s0, we restrict features included in this calculation
to be those with at least 10 non-PMV observations from the two groups combined.
However, we also require that at least 30 features to be included. If total number of
features is less than 30 after applying the 10 non-PMVs restriction, we use the top
30 features with the smallest PMV proportion while combining the two groups.
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Model parameter estimation
Firstly, we use an iterative procedure to obtain our estimates of θk = (µ1k, µ2k, p1k, p2k)
T
and σk for each feature. For a given σk, θk is estimated by maximizing the likelihood
L(θk|σk) =
2∏
j=1
{
nj∏
i=1
f(Xijk|pjk, µjk, σk)
}
(3.6)
where nj is the number of observations in group j, which stays the same for all
features. For a given θk, σk is estimated by maximizing the posterior
p(σ2k|data) ∝
2∏
j=1
{
nj∏
i=1
f(Xijk|pjk, µjk, σk)
}
×
(d0s20
2
) d0
2 σ
2
(
−1− d0
2
)
k
Γ(d0
2
)
exp
(
− d0s
2
0
2σ2k
)
(3.7)
We first plug in the initial estimate of σk into equation (3.7) to find the maximum
likelhood estimate of θk, θˆk. The θˆk is then plugged into equation (3.6) to obtain the
posterior mode, σˆk. By iteratively updating θˆk and σˆk until convergence, we obtain
estimates of θk and σk.
Then we obtain estimates of pij, which are the same for all features, for the next
step. pˆij = nj/N , where nj is the number of observations in group j, and N is the
observation number in both groups. nj will change with updated cluster assignments
which are decided in the next step.
Assigning the clusters
Consider a K-features case. We estimate the set of parameters for each feature
separately then combine information from all K features together. The posterior
probabilities for predicted clusters are defined as:
zˆij =
pˆij
∑K
k=1 f(Xik|pˆjk, µˆjk, σˆk)∑2
h=1 pˆih
∑K
k=1 f(Xik|pˆhk, µˆhk, σˆk)
(3.8)
For the simple two-group cluster analysis, the ith observations can be assigned to
group 1 if zˆi1 > zˆi2, and group 2 otherwise. We used the EM algorithms [71] to
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update the cluster assignment and parameter estimation iteratively until the clusters
no longer change.
To test the performance of the proposed method, we applied five models including
K-means (KC), K-means with simple imputation (KC-I), Hierarchical (HC), Hierar-
chical with simple imputation (HC-I), and DASEV.C to a simulation study and the
applied data analysis. The simple imputation was done by replacing all PMVs by the
smallest non-PMV value divided by
√
2 for each feature.
Since both K-means and DASEV.C are iterative methods and can be sensitive
to the initial assignment, we repeat the tests with multiple starting assignments
and select one test result with the best performance for each method. For KC and
KC-I, we calculate the overall accuracy of each test and choose the one with the
highest accuracy. For DASEV.C, we calculate the overall likelihood for each test
using common features selected by all tests and choose the one with the largest
likelihood.
3.3 Simulation studies
To get a comprehensive evaluation on the performance of DASEV.C, we compared it
to K-means and Hierarchical clustering methods with eight different settings. Those
settings aim to test the clustering analysis performance based on the various combi-
nations of sample size, differential abundance (DA) rate, and the difference in mean
abundance.
Simulation settings
To mimic a real-world scenario, we based our simulation on the human urinary pro-
teome database (HUPD) [74]. Firstly, we applied the differential abundance analy-
sis to the dataset and obtained the necessary parameters including mean, variance,
BPMV proportion, and DL. We restricted the results to include features with less
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than 90% PMVs and expected this would guarantee reasonable values for all param-
eters. Then, we randomly selected all four parameters from the restricted results.
Specifically, each simulated dataset contained 500 features. The abundance level
of each feature was simulated based on the mixture distribution in equation (2.2).
We considered two DA rates, 25% and 50% among all features. We also considered
two different fold changes in the mean abundance, 2-fold and 4-fold between groups.
Finally, we considered a sample sizes of 100 and 200 per group. All combinations of
the sample sizes, DA rates, and fold changes, yield eight different simulation settings
in total (Table 3.1). 100 simulations are conducted for each setting.
Table 3.1: Simulation settings
Setting N (per group) DA rate LFC
S1 100 25% ±log2
S2 100 50% ±log2
S3 200 25% ±log2
S4 200 50% ±log2
S5 100 25% ±log4
S6 100 50% ±log4
S7 200 25% ±log4
S8 200 50% ±log4
Note: DA rate means differential abundance rate,
and LFC refers to log fold change.
For example, to generate a simulated dataset for setting S1, we randomly selected
25% features to have a 2-fold difference in the mean abundance comparing group 1
and group 2. The 25% features were then randomly assigned to have higher or lower
abundance in group 2. Datasets for other simulation settings were generated in the
same manner.
Simulation results
We applied five models including KC, KC-I, HC, HC-I and DASEV.C to the simu-
lation datasets. The main focus is to compare the performance on cluster analysis
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among them. Under most scenarios, DASEV.C obtained the best performance in
predicting the clusters.
Figure 3.1 shows the overall accuracy of all five models for all simulation settings.
S1 to S4 and S5 to S8 are for 2-fold or 4-fold changes in mean abundance, respectively.
For performance details, please refer to supplementary Table A3.1 and A3.2.
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Figure 3.1: Overall cluster prediction accuracy of five models for eight simulation settings.
Note: S1 to S8 are defined in Table 3.1
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We can see from Figure 3.1, as we assumed, the overall accuracy improved as
the DA rate or fold change increased. We also expected that when sample size went
up, the overall accuracy would increase. This was true for DASEV.C. However, we
noticed that K-means and Hierarchical models didn’t perform as expected when the
DA rate was low or fold change was small. If we compare S1 with S3, we can see
KC, HC, KC-I, and HC-I all had higher overall accuracy for a smaller sample size.
When either the fold change or DA rate increased, KC-I and HC-I had higher overall
accuracy with larger sample size . However, KC and HC still had lower accuracy for
the larger sample size. Eventually, when both fold change and DA rate increased,
KC and HC achieved a higher overall accuracy with the larger sample size.
For all simulation settings, KC-I and HC-I had higher accuracy when compared
with KC and HC. The simple imputation improved the performance of K-means and
Hierarchical clustering as we expected. Other than setting S1, DASEV.C maintained
good performance and outperformed not only KC and HC but also KC-I and HC-I.
The median values of overall accuracy are all > 0.9 for S2 to S8.
In addition to the overall accuracy, we also checked the sensitivity and specificity.
Assume we have a control group and a condition group. The sensitivity represents
the proportions of the condition group that are correctly identified as having the
condition. The specificity measures the proportions of the control group that are
correctly identified as not having the condition. Since the two groups are created
without conditions in the simulation study, we use group 1 and group 2 accuracy
to represent sensitivity and specificity, respectively. The ideal situation is that the
accuracy is high for both groups.
We noticed that accuracy for a group could range from less than 0.1 to more than
0.9 when the overall accuracy is low. Figure 3.2 and 3.3 display the accuracy by groups
of five models for S1 to S4 and S5 to S8, respectively. When fold change in mean
abundance was small (Figure 3.2), KC and HC failed to achieve good accuracy for
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both groups at the same time. We can see that when the accuracy for one group was
high, it turned out to be low for the other group. There existed a trade-off on accuracy
between two groups. Comparing to KC and HC, with imputation, KC-I and HC-I
slightly improved the results. However, HC-I still had the problematic pattern. This
trade-off was not addressed for HC by increasing the fold change in mean abundance
(Figure 3.3). Figure 3.3 also suggests that the trade-off got improved, although not
fully addressed, for KC and HC-I. KC-I no longer had the pattern with increased fold
change.
Our proposed method didn’t encounter this trade-off issue. In setting S1, DA-
SEV.C failed to achieve good accuracy for either group. In settings S2 and S3, we
can see that when the accuracy for one group was good, it was also high for the
other group. For all other scenarios, although no obvious pattern can be found for
DASEV.C, the lowest rate for either group was 0.99. Therefore, the trade-off was not
a concern for the proposed method.
Figure 3.2: Cluster prediction accuracy by groups of five models for simulation set-
tings S1 to S4.
Note: S1 to S4 are defined in Table 3.1
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Figure 3.3: Cluster prediction accuracy by groups of five models for simulation set-
tings S5 to S8.
Note: S5 to S8 are defined in Table 3.1
We then investigated the sizes of clusters predicted by the five models. KC and
HC had the tendency to cluster all observations into one group. The cluster sizes
were related to group accuracy. Table 3.2 summarize the minimum cluster sizes of
the five models for all simulation settings.
HC had the most extreme cluster sizes. For example, in scenario S6, the most
uneven cluster sizes are 15 for one group 1 and 185 for the other. The accuracies for
the two groups are 0.09 and 0.94, respectively. KC had a similar tendency, but not
as extreme as HC. With imputation, KC-I tended to cluster more evenly than KC in
all settings. However, compared to HC, HC-I only achieved noticeable improvement
when both fold change and DA rate increased (S6 and S8). DASEV.C maintained
the best cluster sizes, which were the closest to the true sizes, in all scenarios.
When poor cluster sizing is present, the overall accuracy is a biased measure to
assess the performance of the cluster analysis. One commonly used method to give
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Table 3.2: Minimum predicted cluster sizes of five models for all simulation settings
100 Obs per group 200 Obs per group
S1 S2 S5 S6 S3 S4 S7 S8
DASEV.C 81 84 99 100 175 198 200 200
KC 64 53 62 67 88 74 116 151
HC 27 22 23 15 35 37 41 39
KC-I 72 63 91 97 121 163 187 195
HC-I 20 20 30 81 55 31 84 170
Note: The five models are the proposed method (DASEV.C), K-means
(KC), K-means with imputation (KC-I), Hierarchical (HC), and Hierar-
chical with imputation (HC-I). S1 to S8 are defined in Table 3.1.
more appropriate assessment for clusters is Rand-Index. The original design and its
extensions are widely used in addressing issues found in cluster analysis [88–90]. We
applied the adj.rand.index function in R package pdfCluster [91] to get an Rand-
Index measurement for our simulation study. The function is designed based on the
paper wrote by Hubert and Arabie (1985) [88, 91].
Figure 3.4 shows the summarized Rand-Index for all simulation settings. The
detailed numeric results can be found in supplementary Table A3.3. Range of the
Rand-Index is from -1 to 1. Negative values mean worse clustering results. While
comparing the performance among five models, Figure 3.4 presents similar pattern as
shown in Figure 3.1. However, when the trade-off issue was presented, the differences
in Rand-Index scores between DASEV.C and other models were larger than for overall
accuracy. For example, in setting S3, the median overall accuracy was about 0.6 and
0.9 for KC-I and DASEV.C, respectively. The median Rand-Index was 0.04 for KC-I
and 0.65 for DASEV.C. Therefore, the difference in median Rand-Index (0.61) was
about twice as large for median overall accuracy (0.3).
In conclusion, no models can separate the two clusters appropriately in scenario
S1. In the rest scenarios, DASEV.C outperformed all other models and obtained
reasonable (over 0.6 in S2 and S3) to great (over 0.99) Rand-Index scores on average.
47
Figure 3.4: Rand-Index assessment of the five models for eight simulation settings.
Note: S1 to S8 are defined in Table 3.1
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3.4 Application
To further demonstrate the utility of our proposed method, we also compared DA-
SEV.C to K-means and Hierarchical clustering methods using real-world data analy-
sis. We conducted two studies, one on the HUPD proteomics dataset and the other
on a metabolomics dataset for normal and lung cancer patients offered by Markey
Cancer Center, University of Kentucky [81].
Cluster analysis - HUPD proteomics
Human urinary proteome database (HUPD) data was obtained from urine samples
process by capillary electrophoresis-mass spectrometry (CE-MS). The database con-
tains urine samples from 13,027 patients with 47 different pre-selected pathophysi-
ological conditions. [74]. For method demonstration, we focused on separating 536
Type 1 and 812 Type 2 diabetes patients into two clusters. After applying the previ-
ously mentioned feature inclusion criteria, we obtained a total of 5,350 peptides for
our analysis.
Figure 3.5 displays a heatmap of the 5,350 peptides from all 1,348 diabetes pa-
tients. Those patients are divided into four groups in the figure. From left to right,
the four groups are correctly identified Type 1, Type 2 identified as Type 1, Type 1
identified as Type 2, and correctly identified Type 2 by DASEV.C. One one hand,
the misclassified Type 2 diabetes patients displayed a pattern similar to the truly
identified Type 1 patients. On the other hand, those misclassified Type 1 patients
had a pattern similar to truly identified Type 2 patients.
Table 3.3 summarizes the clustering results for HUPD diabetes patients. DA-
SEV.C obtained the highest overall accuracy (61%) and maintained reasonable ac-
curacy for both Type 1 (57%) and Type 2 (64%) diabetes. KC-I didn’t get any
improvement from the imputation. Its performance was similar to KC. Compared to
HC, HC-I obtained noticeable improvement in the overall accuracy by imputing the
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Figure 3.5: Heatmap of 5,350 peptides by true versus DASEV.C predicted clusters
for 1,348 Type 1 or Type 2 diabetes patients.
missing values. HC had the tendency to group all patients into the same cluster.
Table 3.4 shows the Rand-Index for all five models. DASEV.C had the highest
score. The Rand-Index decreased for K-means method with imputation. KC-I tended
to cluster more Type 2 diabetes patients into Type 1. In contrast, imputation helped
Hierarchical method to obtain a higher Rand-Index. HC-I had more reasonable cluster
sizes after imputation.
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Table 3.3: Cluster analysis results of the five models for HUPD Type 1 and Type 2
diabetes patients.
Cluster size Accuracy
Prediction T1 MT2 T2 MT1 Overall Type 1 Type 2
DASEV.C 308 228 518 294 0.61 0.57 0.64
KC 317 219 391 421 0.52 0.59 0.48
HC 60 476 644 168 0.52 0.11 0.79
KC-I 316 220 378 434 0.51 0.59 0.46
HC-I 423 113 370 442 0.59 0.79 0.46
Note: The five models are the proposed method (DASEV.C), K-means (KC), K-
means with imputation (KC-I), Hierarchical (HC), and Hierarchical with imputation
(HC-I). Cluster sizes are for four prediction groups based on the true and DASEV.C
clusters. The four groups are correctly identified Type 1 (T1), misclassified Type 2
(MT2), correctly identified Type 2 (T2), and misclassified Type 1 (MT1) diabetes
patients.
Table 3.4: Rand-Index of five models for cluster analysis on HUPD Type 1 and Type
2 diabetes patients.
Rand-Index
DASEV.C 0.0497
KC 0.0015
HC -0.0171
KC-I -0.0004
HC-I 0.0273
Note: The five models are the proposed method (DA-
SEV.C), K-means (KC), K-means with imputation
(KC-I), Hierarchical (HC), and Hierarchical with im-
putation (HC-I).
Cluster analysis - metabolomics
We also analyzed a non-small cell lung cancer exosomal lipids profiling dataset re-
ported by Fan et al. (2018) [81]. We focused on separating 39 normal patients and
91 non-small cell lung cancer patients into two clusters. After applying the feature
inclusion criteria, 135 lipid features were considered in our analysis. The molecular
formulae of the lipids were determined by ultrahigh resolution accurate mass spec-
trometry as previously described [81].
Figure 3.6 displays a heatmap of the 135 lipids from all 130 normal and cancer
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patients. Those patients are divided into four groups. From left to right, the four
groups are correctly identified normal, cancer identified as normal, normal identified
as cancer, and correctly identified cancer by DASEV.C. The misclassified cancer
patients displayed a pattern similar to the truly identified normal patients. Likewise,
those misclassified normal patients had a pattern similar to truly identified cancer
patients.
Figure 3.6: Heatmap of 135 lipids by true versus DASEV.C predicted clusters for 130
normal and lung cancer patients.
Table 3.5 presents the clustering results for the metabolomics dataset. KC-I ob-
tained the highest overall accuracy (69%). However, it grouped almost all patients
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into one cluster. Therefore KC-I actually failed the clustering test. Ignoring KC-I,
DASEV.C obtained the best overall accuracy (65%). Although the accuracy for nor-
mal patients was a little low (46%), it was relatively good for cancer patients (74%).
Table 3.5: Cluster analysis results of five models for 130 normal and lung cancer
patients.
Cluster size Accuracy
Prediction NC MLC LC MNC Overall Type 1 Type 2
DASEV.C 18 21 67 24 0.65 0.46 0.74
KC 26 13 41 50 0.51 0.67 0.45
HC 16 23 55 36 0.55 0.41 0.60
KC-I 0 39 90 1 0.69 0.00 0.99
HC-I 14 25 52 39 0.51 0.36 0.57
Note: The five models are the proposed method (DASEV.C), K-means (KC), K-means
with imputation (KC-I), Hierarchical (HC), and Hierarchical with imputation (HC-I).
Cluster sizes are for four prediction groups based on the true and DASEV.C clusters.
The four groups are correctly identified normal (T1), misclassified lung cancer (MT2),
correctly identified lung cancer (T2), and misclassified normal (MT1) patients.
Table 3.6 shows the Rand-Index for all five models. DASEV.C had the highest
and the only positive index score. The Rand-Index did not change significantly for
both K-means and Hierarchical methods with imputation. KC-I tended to cluster
all patients as having cancer. Therefore, although the overall accuracy was high, the
Rand-Index was negative.
Table 3.6: Rand-Index of five models for cluster analysis on lung cancer patients.
Rand-Index
DASEV.C 0.0708
KC -0.0101
HC -0.0042
KC-I -0.0087
HC-I -0.0116
Note: The five models are the proposed method (DA-
SEV.C), K-means (KC), K-means with imputation
(KC-I), Hierarchical (HC), and Hierarchical with im-
putation (HC-I).
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3.5 Discussion
This chapter aims to develop a model-based clustering method for handling the zero-
inflated proteomics and metabolomics data obtained by MS and to compare its per-
formance with standard clustering methods K-means and Hierarchical. To our knowl-
edge, this study is the first to apply such a method in the high-throughput (HTP)
MS study. We demonstrate the potential of this model-based approach to cluster
HTP MS proteomics and metabolomics data.
In general, fixed parameters are used in simulation studies. However, this limits
the complexity existed in MS omics data. We try to mimic the real-world scenarios
to the greatest extent. Therefore, datasets generated in our simulation study were
based on parameters obtained from HUPD proteomics data. Then we conducted the
simulation study using various settings with different sample sizes, DA rates, and fold
changes in mean abundance.
Compare to the standard methods, DASEV.C maintained better performance in
most scenarios. When fold change in mean abundance and DA rate were both small,
the performance of both K-means and Hierarchical with or without imputation de-
creased as the sample size went up. This decrease is against the expectation of a
larger sample size leads to a higher ability to separate the groups. Further investiga-
tion can be done to explore the causes of this phenomenon. DASEV.C performed as
expected and obtained higher accuracy with a larger sample size.
In cluster analyses for both proteomics and metabolomics data, our proposed
model-based method outperformed all other models. Although the accuracy was
only a little higher than 60%, the patterns shown in Figure 3.5 and 3.6 suggest a
good separation in feature abundance between clusters. In the metabolomics study,
we also obtained reasonable accuracy (74%) in clustering cancer patients.
As we mentioned early in the introduction section 1.4, imputation instruments
for handling missing data have to be applied cautiously and no methods can be used
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in general [49, 50]. In all our simulation scenarios, both K-means and Hierarchical
clustering achieved noticeable improvement using a simple imputation technique on
the missing values. However, in real data analysis, this technique didn’t always
work well. In the proteomic study, there performance of K-means after imputation
got worse, while there was an improvement in Hierarchical with imputation. In
the metabolomic study, K-means with imputation failed to separate the data into
different clusters. Hierarchical with or without imputation performed identically.
One advantage of our proposed method is that it doesn’t depend on any imputation
instrument. As we expected, it achieved better results than the standard clustering
methods.
There are also limitations in this study. We only test the performance of the
proposed method in simple two-group scenarios with fixed distribution assumptions.
Future work can be done to examine more distribution assumptions and to allow
more than two clusters. Also, we only tested the method for two clusters with the
same sample size in our simulations. This may not be an issue. In real data analysis,
both the proteomics and metabolomics data have uneven group sizes. Our proposed
method returned reasonable cluster sizes corresponding to the true group sizes. In
addition, the method failed to separate the clusters in the scenario where sample
size, fold change, and DA rate were all small. Future investigation in reducing the
dimension of the dataset is necessary for this scenario. The last limitation is the
processing time. DASEV.C takes a longer time to run, especially for larger samples
and feature numbers. Investigations in faster algorithms are also desired considering
those HTP MS data always have numerous features.
Copyright c© Zhengyan Huang, 2019.
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Chapter 4 dasev: An R Package for Differential Abundance Analysis and
Cluster Analysis with Empirical Bayes Shrinkage Estimation of Variance
4.1 Introduction
With the revolution in “Omics” studies, proteomic and metabolomic studies have
become valuable tools to investigate molecular and cellular biology [1, 10]. High-
throughput (HTP) proteomics and metabolomics data produced by Mass spectrom-
etry (MS) have been used in studies to understand diseases’ biological mechanism,
to identify prognostic and predictive biomarkers, and to develop better treatments.
Different strategies associated with MS technology have been developed to promote
its usage. Appropriately analyzing the voluminous and comprehensive information
obtained through MS technology can lead to a better biomarker identification and
more complete understanding of biological effects [1, 14].
One frequently seen characteristic of the HTP data produced by MS is that the
data is zero-inflated. Those zero values are called point mass values (PMVs). Accord-
ing to the causes, the PMVs can be further classified into biological PMVs (BPMVs),
where the feature is absent from the sample, and technical PMVs (TPMVs), where
the feature is present but its abundance is below the detection limit. Because there is
often a large fraction of PMVs in an MS dataset, statistical analysis needs to account
for the PMVs, preferably to further separate BPMVs and TPMVs, thus to ensure
unbiased and efficient inference.
Differential abundance analysis
Identifying differentially abundant features between groups is the central goal for
many proteomic and metabolomic studies. A number of statistical methods have
been proposed for differential abundance analysis based on zero-inflated MS data.
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To our knowledge, the most efficient method for handling the mixed types of PMVs
is the mixture models proposed by Taylor et al. (2013) [34] as well as Gleiss et
al. (2015) [47]. The mixture model considers PMVs as a mixture of TPMVs and
BPMVs. The TPMVs are treated as left-censored data from a normal distribution.
The BPMVs are considered as a point mass at zero. A likelihood ratio test is proposed
to test whether both the mean parameter of the normal distribution and the point
mass at zero are the same between experimental groups.
The mixture model has been compared with an accelerated failure time (AFT)
model by Taylor et al. [34] and with eight one-part or two-part tests by Gleiss et al.
[47]. The authors from both studies concluded that the mixture model was preferred
in parameter estimation when TPMVs presented in the data, especially when the
proportion of TPMVs was large [34,47]. We noticed that in both papers, the authors
applied fixed parameters in their simulations to limit the total zero proportion from
both BPMVs and TPMVs to be less than 75%. They also applied different restrictions
to the real data analyses that significantly reduced the features included in the final
analysis datasets. The motivating human urinary proteome database (HUPD) used
by Gleiss et al. (2015) contains over 5,600 peptides. They comprised their analysis
dataset to include 25 chronic kidney disease and 25 control patients. After they
applied the restriction on PMV proportion (below 70%), only 787 peptides were left.
In reality, MS data often has features with larger PMV proportions. HUPD dataset
contains large number of peptides with PMV proportion over 90%.
To check the performance of the mixture model on data with larger PMV pro-
portions, we applied the method on an original dataset obtained from HUPD. We
required at least three non-PMVs from two groups combined, and at least one PMV
and one non-PMV for each group to make sure the algorithm could be processed. We
noticed that the mixture model can be unstable in the presence of large portion of
zero values. Better methods to handle these zeros are desired.
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Cluster analysis
Cluster analysis has extensive applications in many fields including biological and
biomedical research. Information obtained from similarities within clusters and dis-
similarities among different clusters have many advantageous applications, such as
biomarker identification [59] and disease diagnostics [60]. Proteomic and metabolomic
studies can be especially helpful in those applications. Currently, only two types of
clustering methods are commonly used for proteomics and metabolomics data. One
is K-means clustering and the other is Hierarchical clustering [44,60,61].
K-means is an iterative descent cluster analysis method and it is considered to be
the most popular one [63]. K-means also belongs to the partitioning algorithms group
[62]. One advantage of K-means is that the algorithms usually converge quickly [64].
Therefore, it is widely applied to large datasets. The concern we have for K-means
clustering is that the iterative algorithms often converge at one of the numerous local
minima rather than the global minimum since it is sensitive to the initial starting
assignment [65].
In contrast to K-means, Hierarchical clustering analysis is not an iterative cluster
analysis method. Therefore, convergence is not an issue. Two strategies for Hier-
archical clustering are agglomerative (bottom-up) and (divisive) top-down. The top
level contains only one cluster with all observations, and the bottom level contains
one cluster for each observation. Starting from the bottom, the agglomerative strat-
egy groups two closest clusters together at each step until reaching the top. On the
other hand, the divisive strategy divides one cluster into sub-clusters with the most
dissimilarity at each step from the top level until reaching the bottom. Each step
returns a hierarchical level, which associates with a unique number of cluster [63,66].
Hierarchical clustering analysis is applied to group features rather than observations
in the proteomics and metabolomics fields [67]. K-means and Hierarchical clustering
methods cannot handle the mixture nature of the PMVs.
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There are also other types of algorithms for cluster analysis. In this chapter, we
focus on the model-based clustering analysis. Model-based methods were frequently
applied to various data types with different underlying assumptions including multi-
variate Gaussian or non-Gaussian [57, 66, 68, 69]. One key advantage of the model-
based methods is the availability to adapt a variety of distribution assumptions when
the standard methods are inadequate [70]. It is capable to adapt the underlying mix-
ture distribution of the MS data. Another advantage is that model-based methods
often apply the EM algorithm [71]. Approximate posterior probabilities for clus-
tering can be calculated using estimated model parameters from the optimization
process [72]. Meanwhile, those estimates can provide deeper insights into causes of
different clusters. To our knowledge, the model-based clustering algorithms have not
been frequently applied in proteomic and metabolomic studies.
4.2 Methods
In Chapter 2, we proposed a method for differential abundance analysis with Bayes
Shrinkage Estimation on Variance (DASEV) and compared the method with the
mixture model. We demonstrated through simulations that our proposed method
controls the false discoveries better than the mixture models. And in Chapter 3, we
extended the method for clustering (DASEV.C). Both simulations and real data anal-
ysis suggest the proposed model-based design outperformed the standard methods in
clustering the proteomics and metabolomics data.
To the best of our knowledge, there is not a software package available to imple-
ment the mixture models. The R code for original mixture models are offered by the
authors [34, 47]. However, there are some computational limitations with the opti-
mization processes. In this chapter, we introduce an R package, dasev, constructed
specially for our two methods and explain its usage.
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Differential abundance analysis
The Model
We focus on two-group comparisons and refer to the two groups as control (group
1) and case (group 2) groups. We assume that the HTP MS data for a proteomic
or metabolomic feature contain two parts, PMVs and non-PMVs, where PMVs are
a mixture of BPMVs and TPMVs. We further assume that non-PMVs follow a log
normal distribution truncated at the DL, where the truncation leads to TPMVs.
Under those assumptions, for a single feature k, the density of the ith observation
in group j, Xijk, follows a mixture distribution [34, 47] with the following density
function
f(Xijk|pjk, µjk, σk) =

pjk + (1− pjk)Φ((λk − µjk)/σ2k), if PMVs
(1− pjk)φ((log(Xijk)− µjk)/σ2k), if non-PMVs
(4.1)
where pjk is the proportion of BPMVs and µjk is the mean parameter for group j
(j = 1, 2) and feature k, σk is the standard deviation and λk is the detection limit
for feature k, and Φ and φ are cumulative distribution and density functions of a
standard normal distribution, respectively. Based on equation (4.1), the non-PMV
observations follow a truncated normal distribution
f(Xijk|Xijk > 0, µjk, σk) = φ((log(Xijk)− µjk)/σ
2
k)
σk[1− Φ((λk − µjk)/σ2k)]
(4.2)
In presence of large fraction of PMVs, parameter estimation based on model (4.1)
can be unstable. In order to improve the estimation, we introduce a prior distribution
for σ2k across all features. Specifically, we consider an inverse-gamma distribution with
shape parameter d0/2 and scale parameter d0s
2
0/2.
σ2k ∼
(d0s20
2
) d0
2 σ
2
(
−1− d0
2
)
k
Γ(d0
2
)
exp
(
− d0s
2
0
2σ2k
)
(4.3)
This prior distribution allows us to borrow information across the ensemble of
features so that more stable variance estimation can be obtained. The hyperparam-
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eters, d0 and s0, are empirically determined from the data as described in the next
subsection.
Determining hyperparameters
We first obtain an initial estimate of σk as the value that maximizes the likelihood
for non-PMVs, i.e. Π2j=1Π
nj
i=1f(Xijk|Xijk > 0, µjk, σk), where µjk is set as the sample
mean of non-PMVs in group j, nj is the number of observations in group j and
the DL is set as the minimal log-transformed non-PMV observation minus 0.1 for
each feature. Note that this initial estimate of σk is only used for the calculation of
hyperparameters. Once the hyperparameters are determined, a more robust estimate
of σk is obtained as described in the next subsection. Let m and v be the sample
mean and variance for the initial estimate of σk across features, respectively. Based
on the inverse gamma distribution and using the method of moments, the d0 and s0
are calculated as follows
d0 =
2m2
v
+ 4 and s0 =
√
m(d0 − 2)
d0
(4.4)
In order to robustly estimate d0 and s0, we restrict features included in this
calculation to be those with at least 10 non-PMV observations from the two groups
combined. However, we also require that at least 30 features to be included. If total
number of features is less than 30 after applying the 10 non-PMVs restriction, we
use the top 30 features with the smallest PMV proportion while combining the two
groups.
Model Parameter estimation
We use an iterative procedure to obtain our estimates of θk = (µ1, µ2, p1, p2)
T and σk.
For a given σk, θk is estimated by maximizing the likelihood
L(θk|σk) =
2∏
j=1
{
nj∏
i=1
f(Xijk|pjk, µjk, σk)
}
(4.5)
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where nj is the number of observations in group j. For a given θk, σk is estimated by
maximizing the posterior
p(σ2k|data) ∝
2∏
j=1
{
nj∏
i=1
f(Xijk|pjk, µjk, σk)
}
×
(d0s20
2
) d0
2 σ
2
(
−1− d0
2
)
k
Γ(d0
2
)
exp
(
− d0s
2
0
2σ2k
)
(4.6)
We first plug in the initial estimate of σk into equation (4.6) to find the maximum
likelhood estimate of θk, θˆk. The θˆk is then plugged into equation (4.5) to obtain the
posterior mode, σˆk. By iteratively updating θˆk and σˆk until convergence, we obtain
estimates of θk and σk.
Hypothesis testing
We suppress k for features in the following functions to make them easier to read.
Our method allows examining the following three hypotheses for each feature:
HM0 : µ1 = µ2 = µ vs H
M
A : µ1 6= µ2
which tests if the group means are different.
HP0 : p1 = p2 = p vs H
P
A : p1 6= p2
which tests if the BPMV proportions are different.
HB0 : µ1 = µ2 = µ and p1 = p2 = p vs H
B
A : µ1 6= µ2 and/or p1 6= p2
which tests if the group means or the BPMV proportions are different. A likelihood
ratio test statistic is used to test each of the three hypotheses. Specially,
For testing HM0 :
TM = log
{∏2
j=1
[∏nj
i=1 f(Xij|p1, p2, µ1, µ2, σ)
]∏2
j=1
[∏nj
i=1 f(Xij|p1, p2, µ, σ)
] } (4.7)
For testing HP0 :
TP = log
{∏2
j=1
[∏nj
i=1 f(Xij|p1, p2, µ1, µ2, σ)
]∏2
j=1
[∏nj
i=1 f(Xij|p, µ1, µ2, σ)
] } (4.8)
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For testing HB0 :
TB = log
{∏2
j=1
[∏nj
i=1 f(Xij|p1, p2, µ1, µ2, σ)
]∏2
j=1
[∏nj
i=1 f(Xij|p, µ, σ)
] } (4.9)
A p-value is obtained based on a χ2 distribution with one degree (for testing HM0
and HP0 ) or two degrees (for testing H
B
0 ) of freedom. The Benjamini and Hochberg
procedure [80] is used to control the false discovery rate (FDR).
Cluster analysis
The Model
We applied the same distribution assumptions as for the differential abundance anal-
ysis. The density of the ith observation for feature k is,
f(Xik|pi1, p1k, µ1k, pi2, p2k, µ2k, σk) =
2∑
j=1
pij
[ {
pjk + (1− pjk)Φ((λk − µjk)/σ2k)
}1−dik
× {(1− pjk)φ((log(Xik)− µjk)/σ2k)}dik ] (4.10)
where pij > 0 are the mixing proportions for group j (
∑2
j=1 pij = 1 ), dik is 0 if Xijk is
PMV and 1 if Xijk is non-PMV, pjk is the proportion of BPMVs and µjk is the mean
parameter for group j,σk is the standard deviation, λk is the detection limit, and
Φ and φ are cumulative distribution and density functions of a normal distribution,
respectively. We also adapt the prior distribution for σ2k as mentioned above.
Parameter estimation
The parameter estimation process is similar to the differential abundance analysis.
Observations are unlabeled in cluster analysis. To get a starting point, we randomly
assign each observation to group 1 or group 2. We firstly applied the parameter
estimation process for the abundance analysis to get estimates on p1k, p2k, µ1k, µ2k,
and σk.
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Then we obtain estimates of pij, which are same for all features, for the next
step. pˆij = nj/N , where nj is the number of observations in group j, and N is the
observation number in both groups. nj will change with updated cluster assignments
which are decided in the next step.
Assigning the clusters
Consider a K-features case. We estimate the set of parameters for each feature
separately, then combine information from all K features together. The posterior
probabilities for predicted clusters are defined as:
zˆij =
pˆij
∑K
k=1 f(Xik|pˆjk, µˆjk, σˆk)∑2
h=1 pˆih
∑K
k=1 f(Xik|pˆhk, µˆhk, σˆk)
(4.11)
For the simple two-group cluster analysis, the ith observations can be assigned
to group 1 if zˆi1 > zˆi2, and group 2 otherwise. We used the EM algorithms [71] to
update the cluster assignment and parameter estimation iteratively until the clusters
no longer change.
4.3 Usage of the package
Package functions
The dasev package depends on the basic library stats [92]. Function optim is used
in our package to process the optimization steps. dasev contains three functions:
DASEV.C, DASEV.DA, and Getsample. It also includes a data matrix simpool for
simulation parameters.
Function DASEV.DA implements the differential abundance analysis. A list in-
cluding feature names, parameter estimates, and p-values for likelihood ratio tests
is returned as the results. Function DASEV.C is designed for cluster analysis. The
function returns a list including the final cluster assignments, probability for each
subject to be clustered into a group, and the cluster sizes. Function DASEV.C de-
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pends on DASEV.DA. Therefore, they have many common arguments. Table 4.1
and 4.2 summarize the input options for DASEV.DA and DASEV.C, respectively.
Common input options used in DASEV.DA are not listed for DASEV.C.
Both functions are designed to take input data as a matrix with rows for features
and columns for subjects/observations. mim.non0n is used to restrict the minimum
number of non-PMVs required for a feature to be included in the analysis dataset. The
largest PMV proportion of the features decreases as this number increases. Users can
choose a value at their own preferences. Notice that larger values reduce the number of
features in the final dataset. requiredn and requiredn2 are applied together to ensure
reasonable number of features will be used to obtain the prior distribution of variance.
We design DL method to have the flexibility and allow users to choose one of three
ways to define the detection limit. DL value should be considered simultaneously
for the chosen DL method. covar should only contain 0 and 1 as group indicators.
This input option is not in function DASEV.C. DASEV.C will generate covar based
on cluster assignments for function DASEV.DA while estimating the parameters. In
addition, for cluster analysis, we don’t need to do model comparisons as we do for the
differential abundance analysis. Therefore, we set test model to be empty to reduce
the function’s processing time.
Function Getsample is designed to generate simulation data based on parameters
randomly selected from simpool. We include the parameter data frame as an example.
Users can apply their preferred parameter data frame. To be more specific, in the data
frame, the rows are for features and columns are detection limits, mean abundances,
BPMV proportions, and standard deviations. The function returns a list including
two data matrices, simdata as the simulated dataset and Parameters as the randomly
selected parameters used to generate the date. The simulated dataset can be directly
applied to function DASEV.DA and DASEV.C. Input options for Getsample are listed
in Table 4.3.
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Table 4.1: Input options for function DASEV.DA
Name Role
indata
Specifies the input data matrix. Rows are features and
columns are subjects.
covar
A vector of comparison group values. This vector should
only contain 0 and 1 as indicators for two different groups.
min.non0n
The minimum number of nonzero observations for two
groups combined together. Default and the minimum value
is 3.
requiredn
The minimum number of nonzero obs while getting prior
distribution of variance. Default value is 10.
requiredn2
The minimum number of features while getting prior
distribution of variance. Default value is 30.
DL method
Specifies the detection limit method. The options are: Fixed
Difference (default): for each feature, DL is the minimum
value for all nonzero observation minus a number specified
by DL value, Fixed Rate: for each feature, DL is the
minimum value for all nonzero observation divided by a
number specified by DL value, Fixed Value: DL is the same
value (a number specified by DL value) for all features.
DL value
Custom specified number. Default is 0.1 for “Fixed
Difference”.
maxit MLE
The maximum number of iterations while re-estimating the
model parameters. The default is 100.
maxit
The maximum number of iterations applied to the
optimization function.
test model
A vector of models to be tested. The default value is
c(“Both”,“Mean”,“Pzero”).The default is to achieve all
three comparisons listed as follow: If test model contains
“Both”, the function compares both difference in group
means and BPMV proportions (4.9), If test model contains
“Mean”, the function compares difference in group means
(4.7), If test model contains “Pzero”, the function compares
difference in BPMV proportions (4.8).
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Table 4.2: Input options for function DASEV.C
Name Role
. . .
Same arguments excluding covar and text model as function
DASEV.DA.
test n
The number of different starting groups to be tested.
Defaults to 10.
MAX iter
The maximum number of iterations while re-assigning the
cluster groups. The default is 50.
Table 4.3: Input options for function Getsample
Name Role
numc Specifies the number of features. Defaults to 1000.
numobs
Specifies the number of observations per group. Defaults to
100.
pdiff
Specifies the percentage of differentially abundant features.
Defaults to 0.2.
lfc
The log fold change value as the difference in group means.
Default to NULL. The value can be a single number or a
numeric vector. For example, lfc=c(log(2),-log(2)).
pzerodiff
The ratio for odds of BPMVs in two groups. Defaults to
NULL. The value can be a single number or a numeric
vector. For example pzerodiff=c(0.5,2).
simpool
A data frame contains detection limit, mean, BPMV
proportion, and standard deviation. Simulation parameters
are randomly sampled from this data frame.
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Examples: Generating Simulation data
Example 1: use function Getsample to generate a simulation dataset with difference
in group means.
To generate a dataset that only has a difference in group means, pzerodiff needs
to be NULL. Users may specify the feature numbers, group size, percentage of differ-
entially abundant features, and log fold change in group means. Consider a dataset
with 500 features and 200 observations per group, where 25% of the features are
differentially abundant with a 2-fold difference in the log odds ratio. The function
will generate a list that contains two data matrices. We display partial results to
illustrate the output.
> sim1 = Getsample(numc=500, numobs=200, pdiff=0.25, lfc=c(log(2),-log(2)),
+ pzerodiff=NULL, simpool=simpool)
> attributes(sim1)
$names
[1] “simdata” “Parameters”
> simdata1 = sim1$simdata
> paradata1 = sim1$Parameters
> simdata1[1:5,1:10]
P1 P2 P3 P4 P5 P6 P7 P8 P9 P10
F1 0 0 0 0 0 0.0000 0 178.7677 0 0
F2 0 0 0 0 0 0.0000 0 0.0000 0 0
F3 0 0 0 0 0 0.0000 0 0.0000 0 0
F4 0 0 0 0 0 141.1863 0 0.0000 0 0
F5 0 0 0 0 0 0.0000 0 0.0000 0 0
> paradata1[1:2,]
DL mu0 p0 sd mu1 p1
F1 2.227278 5.630664 0.9041916 0.9125874 6.323811 0.9041916
F2 3.659804 7.099050 0.8429807 0.7282978 6.405903 0.8429807
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Example 2: use function Getsample to generate a simulation dataset with difference
in group BPMV proportions.
To generate a dataset that only has a difference in BPMV proportions, lfc needs
to be NULL. Consider a dataset with 500 features and 200 observations per group,
where 25% of the features are differentially abundant with a 2-fold difference in the
log odds ratio of BPMV proportions.
> sim2 = Getsample(numc=500, numobs=200, pdiff=0.25, lfc=NULL,
+ pzerodiff=c(2,0.5), simpool=simpool)
> simdata2 = sim2$simdata
> paradata2 = sim2$Parameters
> simdata2[1:5,1:10]
P1 P2 P3 P4 P5 P6 P7 P8 P9 P10
F1 0 0.0000 0 0 0.0000 0 0 0 27.66161 0
F2 0 0.0000 0 0 0.0000 0 0 0 0.0000 0
F3 0 0.0000 0 0 25.93399 0 0 0 0.0000 0
F4 0 270.2127 0 0 211.49901 0 0 0 0.0000 0
F5 0 0.0000 0 0 0.0000 0 0 0 0.0000 0
> paradata2[1:2,]
DL mu0 p0 sd mu1 p1
F1 3.282694 5.314420 0.7445110 1.1563329 5.314420 0.8535469
F2 1.703359 4.236925 0.9268130 1.0113099 4.236925 0.9620166
Examples: Differential abundance analysis
Example 3: use simulated dataset from Example 1 for a differential abundance
analysis testing only for group means.
We applied default values for most input options and changed test model to only
include “Mean”. covar is c(rep(0,200), rep(1,200)) since there are 200 observations
in each group.
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>DA1 = DASEV.DA(indata=simdata1, covar=c(rep(0,200),rep(1,200)), min.non0n=3,
+ requiredn=10, requiredn2=30, DL method= “Fixed Difference”, DL value=0.1,
+ maxit MLE=100, maxit=1000, test model=c(“Mean”))
> attributes(DA1)
$names
[1] “feature names” “pvalue” “pvalue mean” “pvalue zero” “DL” “estimates”
> rbind(feature=DA1$feature names[1:5],pvalue=round(DA1$pvalue mean[1:5],5))
[,1] [,2] [,3] [,4] [,5]
feature “F1” “F2” “F3” “F4” “F5”
pvalue “0.11265” “0.00026” “0.04148” “0.13798” “0.24977”
> estimates = DA1$estimates
> rownames(estimates) = DA1$feature names
> estimates[1:2,]
beta.1 beta.2 gamma.1 gamma.2 sd
F1 5.639717 0.4936116 -2.228217 0.37786164 0.9569086
F2 7.123950 -0.7531564 -1.479566 -0.13860030 0.7924915
According to the above results, we can calculate group means, BPMV proportions,
variance, and q-value for each feature, and make inference based on the results.
> qvalue = p.adjust(DA1$pvalue mean,method = “BH”)
mu0 mu1 p0 p1 variance qvalue
F1 5.64 6.13 0.90 0.86 0.91 0.38
F2 7.12 6.37 0.81 0.83 0.63 0.003
Example 4: use simulated dataset from Example 2 for a differential abundance
analysis testing only for BPMV proportions.
We applied default values for most input options and changed test model to only
include “Pzero”. covar is still c(rep(0,200), rep(1,200)).
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>DA2 = DASEV.DA(indata=simdata2, covar=c(rep(0,200),rep(1,200)), min.non0n=3,
+ requiredn=10, requiredn2=30, DL method= “Fixed Difference”, DL value=0.1,
+ maxit MLE=100, maxit=1000, test model=c(“Pzero”))
> rbind(feature=DA2$feature names[1:5],pvalue=round(DA2$pvalue zero[1:5],5))
[,1] [,2] [,3] [,4] [,5]
feature “F1” “F2” “F3” “F4” “F5”
pvalue “0.01759” “0.7989” “0.37948” “0.12344” “0.54625”
> estimates = DA2$estimates
> rownames(estimates) = DA2$feature names
> estimates[1:2,]
beta.1 beta.2 gamma.1 gamma.2 sd
F1 5.393841 -0.0962507 -1.120367 -0.6187867 1.0960379
F2 4.148870 0.4001086 -3.051381 -0.1258378 0.8722575
Likewise, we can calculate group means, BPMV proportions, variance, and q-value
for each feature, and make inference based on the results.
> qvalue = p.adjust(DA2$pvalue zero,method = “BH”)
mu0 mu1 p0 p1 variance qvalue
F1 5.39 5.30 0.75 0.85 1.2 0.17
F2 4.15 4.55 0.95 0.96 0.76 0.96
Examples: Cluster Analysis
Example 5: use simulated dataset from Example 1 for a cluster analysis.
We applied default values for all input options. test n is 10, thus 10 tests are
done with 10 different starting cluster assignments are tested. Those tests return
likelihood estimates for each feature. Cumulative likelihood is calculated for each
test with common features used in all tests. Results from the test with the largest
likelihood are in the final output.
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> Cluster1 = DASEV.C(indata=simdata1, test n=10, min.non0n=3, requiredn=10,
+ requiredn2=30, DL method= “Fixed Difference”, DL value=0.01, MAX iter=50,
+ maxit MLE=100, maxit=1000)
While the function is process, information on test number and group assignments are
printed:
Starting group assignment number:1
Different Predictions:23
Different Predictions:6
Different Predictions:2
Different Predictions:2
Different Predictions:0
iter time5
Starting group assignment number:2
. . .
Starting group assignment number:10
Different Predictions:27
Different Predictions:5
Different Predictions:2
Different Predictions:1
Different Predictions:0
iter time5
> attributes(Cluster1)
$names
[1] “cluster” “Prob” “iter” “Loglike” “Size”
> Cluster1$Size
[1] 200 200
> Pred = ifelse(Cluster1$cluster==0,“group2”,“group1”)
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> True = c(rep(“group1”,200),rep(“group2”,200))
> table(Pred,True)
True
Pred group1 group2
group1 117 83
group2 83 117
The overall accuracy for this cluster analysis is 0.585.
Example 6: use simulated dataset with larger fold change in group means for a
cluster analysis.
We generated a simulated dataset with a 4-fold change in group means. Every-
thing else stayed same as Example 1. Then we applied DASEV.C to process the
cluster analysis. This time, we reduced the test numbers to 5.
> sim3 = Getsample(numc=500, numobs=200, pdiff=0.25, lfc=c(log(4),-log(4)), pze-
rodiff=NULL, simpool=simpool)
> simdata3 = sim3$simdata
> Cluster2 = DASEV.C(indata=simdata3, test n=5, min.non0n=3, requiredn=10,
+ requiredn2=30, DL method= “Fixed Difference”, DL value=0.01, MAX iter=50,
+ maxit MLE=100, maxit=1000)
> Cluster2$Size
[1] 198 202
> Pred = ifelse(Cluster2$cluster==0,“group1”,“group2”)
> True = c(rep(“group1”,200),rep(“group2”,200))
> table(Pred,True)
True
Pred group1 group2
group1 197 1
group2 3 199
The overall accuracy for this cluster analysis is 0.99.
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Users can apply their own parameters to the simulation and test the performance
of the function for scenarios we don’t cover in this study. Different seeds may return
various results for the same setting. Users can set the seed to get a reproducible
result.
4.4 Discussion
In this chapter, we developed the R package dasev and presented the method, us-
age, and implementation of its functions. The two main functions DASEV.DA and
DASEV.C are designed for the differential abundance and cluster analysis we have de-
tailed in Chapter 2 and Chapter 3, respectively. The two proposed methods achieved
the expected performance. This package also contains a parameter data frame simpool
for simulation purpose. It is convenient for the users to conduct a quick simulation
study and get familiar with the input options for the function. It is also helpful for
the users to understand the structure of function outputs easily.
The package also has several limitations. Both the differential abundance and
cluster analysis are limited to two groups. Therefore, DASEV.DA will not process
the differential abundance analysis, and DASEV.C will only result in two clusters
for more than two groups. In the future, we would like to address this issue and
generalize the functions to handle multiple groups.
Another limitation is the processing time associated with the iterative nature of
the methods. When the size of the data is small, the processing time is reasonable.
However, when the data size is large (for example, the HUPD dataset with thousands
of observations and features), the function can take a longer time to run. For example,
the real data cluster analysis for HUPD proteomics data took more than 2 hours for
one test. Hierarchical cluster only took several minutes. We would like to investigate
more efficient algorithms to reduce the processing time in the future.
In addition, this package is limited to the distribution assumptions we listed in
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the method section 4.2. Further development can easily generalize the functions in
this package to other distribution assumptions.
In summary, dasev is the first R package designed for zero-inflated mass spec-
trometry omics data, specially, proteomics and metabolomics data. The functions
in this R package can be utilized to perform two-group differential abundance and
cluster analysis for those data. By adding the inverse-gamma prior distribution of
variance, we improved the unstable estimation issue presented in the original mixture
models and obtained better control on FDR. In addition, the extended model-based
clustering method shows its potentials in cluster analysis for omics data. The param-
eter data frame and the function to generate simulated data can be helpful for users
to get familiar with the package. We plan to make necessary modifications to the
package and submit it to Bioconductor when it is ready. Meanwhile, all functions are
available upon request.
Copyright c© Zhengyan Huang, 2019.
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Chapter 5 Summary and Discussion
5.1 Summary
We explored and evaluated currently available methods for the differential abundance
and cluster analysis within the proteomics and metabolomics fields. We found un-
desirable performances due to their limitations. Thus, inference based on the results
may be biased. Methods that can better separate the biological and technical PMVs
are desired.
In this dissertation, we aimed to develop one differential abundance (DA) and one
clustering method specially for zero-inflated MS omics data. We expected they would
outperform currently available methods. We also aimed to develop a package as an
implementation tool for the two methods.
We adapted the inverse-gamma distribution as the prior for variances across all
features to a mixture model and developed our proposed method DASEV. We have
seen obvious improvements in the DA analysis by applying this Bayes shrinkage
estimation on variance. We obtained precise estimates for all parameters. In addition,
DASEV achieved better control over false discovers.
Based on the great performance of DASEV, we extended it for cluster analysis.
DASEV.C was designed to separate the zero-inflated data into two clusters with dif-
ferent clinical conditions. The accuracy of the method is desirable in certain scenarios.
R package dasev was developed as a tool to implement the DA and cluster meth-
ods. In addition, the package includes a function for generating simulation dataset
as well as a data frame for necessary simulation parameters.
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5.2 Discussion
Strengths
In proteomic and metabolomic studies, it is important to separate biological and
technical PMVs during the downstream analysis. Compared to currently applied
methods, the proposed methods obtained better performance in both differential
abundance and cluster analysis.
One of the major strengths of this study is the complexity in the simulations. Pre-
vious proteomic and metabolomic studies applied fixed parameters to all features in
their simulations. Thus limited the complexity of the simulated data. We randomly
selected different parameters for each feature in a single simulation. In addition, dif-
ferent from most studies, we applied no restriction on the maximum PMV proportion
for a feature to be included in the analysis dataset. By giving the flexibility to those
parameters, our simulations mimicked the real-world scenarios to a great extent.
Another strength is that we demonstrated both methods outperformed the com-
parison methods not only in the designed simulation settings but also in the real-world
settings. DASEV detected more potential peptides or lipids in the read data analysis
as we detailed in Chapter 2. DASEV.C obtained the highest accuracy and best group
sizes for both the proteomics and metabolomics cluster analysis as we described in
Chapter 3. The performance of DASEV.C was consistent between simulations and
real data analysis. K-means and Hierarchical cluster methods were unstable in pre-
dicting the clusters.
The last strength we would like to emphasize is the R package dasev. Our package
gives flexibility to most input options. Our functions don’t have a convergence issue,
which was seen in previous studies, due to the fixed boundaries [34,47]. We consider
our package to be user-friendly. Shortly after we modify the code to meet the standard
as a Bioconductor package, it will be available for researchers.
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Limitations and future directions
There are also some limitations in this study which we plan to address in the future.
Due to the scope of this study, we only tested the performance of two proposed meth-
ods in simple two-group scenarios with fixed distribution assumptions. Moreover, the
package functions are coded only for two groups. In reality, data with multiple groups
and different distributions are frequently seen in the omics field. In the future, we
will generalize the methods for multiple groups as well as different distributions, and
update the package functions simultaneously.
Another limitation is that we assumed both groups had same variance for each
feature. Although we obtained desirable results in this study, this assumption might
not hold in other studies. In the future, we plan to update our method to allow
different variances among groups. We also plan to give flexibility for users to choose
same or different variances as one input option in the package functions.
The last limitation is the inability of our clustering method in certain simulation
setting and the performance in applied data analyses. In a real-world setting, obser-
vation number and differences between groups are fixed for the data. Those cannot
be changed once the experiment is done. In addition, the data may contain other
confounding factors which can be measured or unmeasured. One way to improve the
performance is to control on the confounders. We will improve our method to be
able to handle other factors. Thus, the model can account for confounding factors.
The other alternative is feature selection. If we can restrict the features we use in
cluster analysis to have differential abundances between the interested groups, better
clustering results will be achieved. Future investigation in suitable feature selection
methods is needed. We expect a noticeable improvement in clustering with filter
features.
Copyright c© Zhengyan Huang, 2019.
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Appendices
A1 Supplementary results for differential abundance analysis
Hyperparameters in Inverse-gamma distribution
We assume σ2k follows an inverse-gamma distribution with shape parameter d0/2 and
scale parameter d0s
2
0/2.
σ2k ∼
(d0s20
2
) d0
2 σ
2
(
−1− d0
2
)
k
Γ(d0
2
)
exp
(
− d0s
2
0
2σ2k
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The first and second moments for inverse-gamma distribution are
E(σ2k) =
d0s
2
0/2
d0/2− 1
E((σ2k)
2) =
(d0s
2
0/2)
2
(d0/2− 1)(d0/2− 2)
Therefore, the mean (m) and variance (v) for inverse-gamma are
m = E(σ2k) =
d0s
2
0/2
d0/2− 1
v = E((σ2k)
2)− (E(σ2k))2 =
(d0s
2
0/2)
2
(d0/2− 1)2(d0/2− 2)
Then s0 and d0 can be calculated as:
d0 =
2m2
v
+ 4
s0 =
√
m(d0 − 2)
d0
79
Figure A2.1: Fitted inverse gamma curve for variance.
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Figure A2.2: Estimated versus true variance of DASEV and TLK, 200 observations
per group. Panel a and b are TLK and DASEV on full scale, and panel c and d are
TLK and DASEV on reduced scale with estimated variances range from 0 to 2. Red
lines show where the estimated variances equal to the true variances.
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Figure A2.3: Comparisons of estimated parameters for mean and BPMV proportion
from DASEV and TLK with 200 observations per group. Panel a and c are for TLK,
and panel b and d are for DASEV.
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Figure A2.4: Aggregated results for simulations with 200 observations per group.
Panel a and b are log fold change in estimated mean versus variance in a single
simulation for TLK and DASEV, respectively. Filled points are for features with
PMVs larger than 90%. Panel c is the average TPR for top 150 features on 200
simulations. Panel d is the average counts (with rate) of true and false positive
discoveries at three reported FDR points on 200 simulations.
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Figure A2.5: Average results of TPR and FDR on 100 simulations for sample size
100 and 200 in testing difference in BPMV proportions. Panel a and c are TPR for
top ranked features with sample size of 100 and 200, respectively. Panel b and d are
counts (with rates) of true and false positive discoveries at three reported FDR points
with sample size of 100 and 200, respectively.
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Figure A2.6: Aggregated results for sub-sampling analysis with 200 observations per
group. Panel a and b are log fold change in estimated mean versus variance in a
single analysis for TLK and DASEV, respectively. Filled points are for features with
PMVs larger than 90%. Panel c is the average TPR for top 300 features on 100
sub-sampling analyses. Panel d is the average counts (with rate) of true and false
positive discoveries at three reported FDR points on 100 sub-sampling analyses.
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A2 Supplementary results for cluster analysis
Table A3.1: Simulation results for setting S1 to S4.
Table A3.2: Simulation results for setting S5 to S8.
Table A3.3: Summarized Rand-Index for all settings.
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Table A3.1: Simulation results for setting S1 to S4.
Note: The five models are the proposed method (DASEV.C), K-means (KC), K-means with imputation (KC-I), Hierarchical (HC), and Hierarchical
with imputation (HC-I). S1 to S4 are defined in Table 3.1.
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Table A3.2: Simulation results for setting S5 to S8.
Note: The five models are the proposed method (DASEV.C), K-means (KC), K-means with imputation (KC-I), Hierarchical (HC), and Hierarchical
with imputation (HC-I). S5 to S8 are defined in Table 3.1.
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Table A3.3: Summarized Rand-Index for all settings.
Note: The five models are the proposed method (DASEV.C), K-means (KC), K-means with imputation (KC-I), Hierarchical (HC), and Hierarchical
with imputation (HC-I). S1 to S8 are defined in Table 3.1.
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A3 R package manual
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